Chemical genetic interactions of New Zealand bee products in *Saccharomyces cerevisiae*

Nazmi bin Harith Fadzilah

A thesis submitted to Victoria University of Wellington in fulfilment requirements for the degree of Masters of Science in Biotechnology

2015
Abstract

Propolis, bee venom and bee pollen all have been used by humans traditionally for various medicinal purposes. Studies of these products have been limited primarily to antimicrobial, antifungal, anticancer and free radical scavenging properties. The mechanisms of action of these products remain largely unknown. This study investigates the biological effects of propolis, bee venom and bee pollen using chemical genomics and the yeast model organism. These products are screened against genome-wide yeast mutant libraries to determine the genes, proteins, and pathways that are targets of these products. I identified that propolis chelates iron and consequently creates an iron-deficient condition, which results in the upregulation of plasma membrane and vacuolar high-affinity iron transporters to maximise iron acquisition. Bee venom inhibited the biosynthesis of phosphatidylcholine via Opi3p that catalyses the final two steps of phosphatidylcholine biosynthesis within the CDP-ethanolamine pathway. Bee pollen showed a potential effect on GDP-mannose transport in which the GDP-mannose transport mutants confer hypersensitivity against bee pollen treatment.
Acknowledgement

I would like to display my gratitude to all my friends and families who have helped me throughout the duration of my thesis work. Firstly, my supervisor Dr Andrew Munkacsi, thank you for taking me under your care until the completion of my Master’s degree. Thank you for giving me the freedom and encouraging me to operate independently and try new things as I saw fit. Without your help and guidance I would not have developed the same level of practical skill nor critical thinking I now have. Also I would like to extend my thanks to other faculty members associated with our lab; Professor Paul Atkinson, David Maass, Professor John Miller, Associate Professor and Paul Teesdale-Spittle for their helpful advice and feedback especially in our meetings.

To all of the Chemical Genetics lab group, you have always provided an enjoyable environment from which genuine friendships have developed. In particular I would like to thank Dinidu, Seesei, James, Christina and Namal for all their guide and advice in troubleshooting my experiments and in handling expensive equipment. Personal thanks to Bede for various invitations to his barbeque events. Honestly, it was my first kiwi barbeque experience and I really learned a lot about kiwi culture from you mostly. And also to Aidan, Liam, Eli, Mona, Brett, Amy, Tanisha, Natalie and Brett for their help and company.

Finally I would like to thank my family for all their support. Particularly my parents who have always encouraged me to follow my passions although we are thousands of miles apart, without your support I would simply not have been able to take my studies this far. To all my Malaysian friends who have always been like a family to me. Being with all of you makes me forget that I am still in New Zealand, struggling to finish my master’s thesis.
Abstract......................................................................................................................... 1
Acknowledgements........................................................................................................... 2
Table of contents ............................................................................................................. 3
Table of figures .................................................................................................................. 6
Table of tables ................................................................................................................... 7
List of abbreviations .......................................................................................................... 8
1.0 Introduction .................................................................................................................. 9
  1.1 Natural products demand as health food a nutritional supplement ......................... 9
  1.2 Bee products’ therapeutic use and pharmacological benefits ..................................... 9
    1.2.1 Propolis .............................................................................................................. 9
    1.2.2 Bee venom ....................................................................................................... 11
    1.2.3 Bee Pollen ........................................................................................................ 12
  1.3 Yeast as model organism ............................................................................................ 13
    1.3.1 Advantage of using yeast as model organism .................................................... 13
    1.3.2 Ability to elucidate bioactivity on non-essential and essential genes .................. 13
    1.3.3 Feasibility of yeast to elucidate biological activity on protein expression and localisation .............................................................................................................. 15
  1.4 Chemical genetics to elucidate bee products’ mode of action in yeast ......................... 15
2.0 Methods and materials ............................................................................................... 18
  2.1 Yeast strains ............................................................................................................... 18
  2.2 Growth media and components .................................................................................. 18
  2.3 Preparation of bee products ...................................................................................... 20
    2.3.1 Preparation of propolis extract ........................................................................ 20
    2.3.2 Preparation of bee pollen extract .................................................................... 20
    2.3.3 Preparation of bee venom ................................................................................ 21
  2.4 Dose response studies ................................................................................................. 21
    2.4.1 Propolis and bee pollen broth dose response .................................................... 21
    2.4.2 Bee venom broth dose response ...................................................................... 23
    2.4.3 Propolis/ bee venom / bee pollen agar dose response .................................... 24
  2.5 Homozygous deletion library and DAMP library yeast colonies screening & image acquisition analysis .............................................................................................................. 24
    2.5.1 1536-colonies array screening ......................................................................... 25
    2.5.2 1536-colonies array analysis ............................................................................. 25
5.0 Bee pollen results and discussion ................................................................. 103

5.1 Results .............................................................................................................. 103

5.1.1 Methanolic fraction of bee pollen showed greater inhibition compared to crude fraction in broth and agar media ................................................................. 103

5.1.2 Bee pollen agar screen did not possess any biological process enrichment .......... 105

5.1.3 Broth dose response of GDP-mannose biosynthesis and transport deletion mutant strains indicate hypersensitivity in another GDP-mannose transport gene .......... 107

5.1.4 Opera image analysis of yeast GFP for GDP-mannose biosynthesis and transport strains indicates no changes in GFP fluorescence with bee pollen treatment .......... 110
Table of Figures

Figure 1.1 Chemical genetic interactions can reproduce a synthetic lethal interactions .......... 16
Figure 3.1 Propolis crude and methanolic fraction broth and agar dose response ................. 34
Figure 3.2 his3Δ border strains 1536-array agar dose response ........................................ 36
Figure 3.3 Broth dose response under Iron supplementation (100µM FeCl₂) ......................... 39
Figure 3.4 Broth dose response under different metal ion supplement ................................... 53
Figure 3.5 Opera GFP fluorescence intensity and localisation analysis. .............................. 58
Figure 3.6 Propolis chelates iron ion and induces iron depravation. .................................. 75
Figure 4.1 Bee venom broth and agar dose response ......................................................... 82
Figure 4.2 Residual growth PC metabolism-related deletion mutant strains at mid-log phase and
stationary phase ........................................................................................................ 85
Figure 4.3 Opera GFP fluorescence intensity and localisation analysis ............................... 87
Figure 4.4. PC quantification assay analysis ........................................................................ 97
Figure 4.5. Bee venom inhibits PC biosynthesis via Opi3p .................................................. 102
Figure 5.1 Bee pollen crude and methanolic fractions broth and agar dose response .......... 104
Figure 5.2 Categorisation of all positive from bee pollen screening .................................... 106
Figure 5.3 Broth dose response of GDP-mannose biosynthesis and transport related deletion
mutant strains ............................................................................................................ 107
Figure 5.4 Opera GFP fluorescence intensity and localisation analysis .............................. 111
Figure 5.5 Bee pollen interferes GDP-mannose transport by blocking Vrg4p or Gda1p activity .... 116
Table of tables

**Table 1** Tabulated residual growth of select deletion strains with or without 100 µM FeCl₂ after 24 hours inoculation ........................................................................................................................................... 50

**Table 2** Tabulated residual growth of select deletion strains under bee pollen treatment after 16 hours inoculation ........................................................................................................................................... 109

**Table A.1.1** Top ten most enriched GO term for biological processes from propolis homozygous deletion library screen ........................................................................................................................................... 127

**Table A.1.2** Top ten most enriched GO term for biological processes from propolis DAmP library screen ........................................................................................................................................... 127

**Table A.2.1** Top ten most enriched GO term for biological processes of bee venom yeast homozygous deletion library screen ........................................................................................................................................... 128

**Table B.1.1** Propolis validated hits from yeast homozygous deletion library screen ............................................. 129

**Table B.1.2** Propolis validated hits from yeast DAmP library screen .............................................................................. 131

**Table B.2.1** Bee venom validated hits from yeast homozygous deletion library ....................................................... 133

**Table B.2.2** Bee venom validated hits from yeast DAmP library screen ....................................................................... 138

**Table B.3.1** Bee pollen validated hits from yeast homozygous deletion library screen ........................................... 139

**Table B.3.2** Bee pollen validated hits from yeast DAmP library screen ................................................................. 139
### List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CaCl₂</td>
<td>Calcium chloride</td>
</tr>
<tr>
<td>ClonNat</td>
<td>Nourseothricin</td>
</tr>
<tr>
<td>DAMP</td>
<td>Decreased abundance by mRNA perturbation</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl Sulfoxide</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetetraacetic Acid</td>
</tr>
<tr>
<td>FeCl₂</td>
<td>Iron chloride</td>
</tr>
<tr>
<td>G418</td>
<td>Geneticin</td>
</tr>
<tr>
<td>GDP</td>
<td>Guanosine diphosphate</td>
</tr>
<tr>
<td>GFP</td>
<td>Green fluorescent protein</td>
</tr>
<tr>
<td>GO</td>
<td>Gene Ontology</td>
</tr>
<tr>
<td>MgCl₂</td>
<td>Magnesium chloride</td>
</tr>
<tr>
<td>MnCl₂</td>
<td>Manganese chloride</td>
</tr>
<tr>
<td>OD</td>
<td>Optical density</td>
</tr>
<tr>
<td>ORF</td>
<td>Open reading frame</td>
</tr>
<tr>
<td>PA</td>
<td>Phosphatidic acid</td>
</tr>
<tr>
<td>PC</td>
<td>Phosphatidylcholine</td>
</tr>
<tr>
<td>PE</td>
<td>Phosphatidylethanolamine</td>
</tr>
<tr>
<td>RFP</td>
<td>Red fluorescent protein</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive oxygen species</td>
</tr>
<tr>
<td>SC</td>
<td>Synthetic complete media</td>
</tr>
<tr>
<td>SD</td>
<td>Synthetic dropout media</td>
</tr>
<tr>
<td>SGD</td>
<td>Saccharomyces Genome Database</td>
</tr>
<tr>
<td>snoRNA</td>
<td>Small nucleolar RNA</td>
</tr>
<tr>
<td>xxxΔ</td>
<td>Deletion from deletion mutant array</td>
</tr>
<tr>
<td>ZnCl₂</td>
<td>Zinc chloride</td>
</tr>
</tbody>
</table>
1.0 Introduction

1.1 Natural products demand as health food and therapeutic treatment

Since ancient times, humans have relied on the use of natural resources for treatment of diseases. A common misconception of historical medicinal practices is that our ancestors picked a random assortment of natural resources, be it plants, animal or even earth materials to make a concoction and administer it toward the sick. In fact, there is strong historical evidence of rational medicinal practices based on empirical methods (Alkhateeb, 2014; Borchardt, 2002). With the rich knowledge of natural products as source of medicine, the collective knowledge of the therapeutic benefit of the natural products is far from complete. Moreover, natural products still possess demand in developing countries and approximately half of modern medicines are derived from natural products (Cragg & Newman, 2013).

1.2 Bee products’ therapeutic use and pharmacological benefits

1.2.1 Propolis

Propolis is an accumulation of balsamic resins from plant leaf buds and barks (Ghisalberti, 1979). As it is a collection of resins, the constituents of its composition are found to vary according to season and geographical location (Brown, 1989; Khalil, 2006). It has two natural uses by the honey bees; as a cement to repair and protect the hive and as an antiseptic for the protection of their larvae, honey and combs (Seeley & Morse, 1976).
The historical uses of propolis can be traced back to the time of the greeks, Egyptians, persians and romans where it has been used to cure external and internal wounds and ulcers, painkillers, treating inflammations (Kuropatnicki et al., 2013). To this day, propolis is widely used by practitioners of alternative medicine and administered in different forms primarily as an antiseptic. Among common applications being as ointments for treating external injuries and inflammations and throat lozenge (Castaldo & Capasso, 2002). A number studies that explores biological effects of propolis. Among them is the antimicrobial and antifungal properties of propolis (Elbaz & Elsayad, 2012; Pavilonis et al., 2008; Ozen et al., 2010; Quiroga et al., 2006). There are studies that demonstrated efficacy of propolis as antioxidants and also as tumour suppressing properties (Valente et al., 2011; Li et al., 2007). There are studies that showed how propolis suppressed cancer cell lines and induced apoptosis in fungi (Valente et al., 2011; Castro et al., 2011). However, the mechanism of selective cancer cell suppression and apoptosis induction were unknown to whether the apoptosis was being induced directly or that apoptosis was a consequence of physiological changes caused by propolis.
1.2.2 Bee Venom

Bee venom is traditionally used topically to treat skin diseases and orally to treat arthritis, rheumatism, and cancer (Hider, 1988). The main bioactive compounds of bee venom are melittin, apamin, adolapin and phospholipase A (Lariviere & Melzack, 1996). Melittin, the main active component of bee venom is found to induce leak to phospholipid bilayer (Pratt et al., 2005) and found to exhibit cytotoxicity on a myriad of cancer cell lines by triggering both intrinsic and extrinsic apoptosis without inducing cytotoxicity on normal cells via selectively targeting activated ras oncogenes (Orsolic, 2012; Moon et al., 2006; Jp et al., 2012). Also, it is found that melittin can suppress free radical production via calmodulin (Son et al., 2007). Adolapin is the component that contributes to anti-inflammatory effect of bee venom.

Bee venom has been used in acupuncture, a new alternative therapy termed Bee venom acupuncture. Such therapy has found to reduce and prevent arthritic inflammation when performed in rats (Kwon et al., 2002; Lee et al., 2005). The anti-inflammatory effect of bee venom is mediated via inhibition of iNOS activity and iNOS mRNA expression, and TNF-α production which is contributed by the water soluble fraction comprised of melittin, adolapin, mast cell degranulating (MCD) peptide and phospholipase A (Kwon et al., 2002; Han et al., 2007). Another study demonstrated that bee venom can suppress inflammatory factors and reverse stimulation by inflammatory agent (Yin et al., 2005). Bee venom is also found to exhibit antimicrobial and antifungal effects in numerous studies (Yu et al., 2006; Fennel et al., 1968). Although growth inhibition of various bacterial and fungal species was demonstrated, it remains
unclear whether bee venom directly induces pro-apoptotic signal or alters physiology that leads to apoptosis.

1.2.3 Bee Pollen

Bee pollen refers to the pollen dust which the bees accumulate on their body when collecting nectar (Bruno, 2005). For the honey bees, bee pollen serves as a source for proteins, fats and minerals (Villanueva et al., 2002). Similarly to propolis, the constituents of bee pollen is location- and season-dependent (Campos et al., 2008). For example, bee pollen products from different regions possess different therapeutic effects. The pollen was used by physicians as early as the 12th century and was used increasingly after the development of pollen traps (Bogdanov, 2014).

Although the therapeutic mechanisms of bee pollen are largely unknown, bee pollen is sold to consumers as health food with therapeutic effects including hepatoprotective and anti-inflammatory properties (Pascoal et al., 2014) (Maruyama et al., 2010). In addition, bee pollen improved digestion (Wojciki et al., 1986; Wojciki et al., 1985; Wang et al., 2007). Other benefits which bee pollen was found to possess are antioxidative properties and antimicrobial properties (Fatcova-Sramkova et al., 2013). However, how bee pollen achieved these therapeutic benefits in cellular level had not been investigated.
1.3 Yeast as model organism

1.3.1 Advantage of using yeast as model organism

Yeast (*Saccharomyces cerevisiae*) is well suited to study the mechanism of action of bioactive compounds. Yeast genes and proteins were conserved (Tugendreich et al., 1994). The data of the compound activity on yeast can be translated into other eukaryote subjects to a good degree. The yeast genome is well characterised and the compendium of information of genes known to yeast is available in *Saccharomyces* Genome Database (SGD; http://www.yeastgenome.org). Furthermore, yeast is the only organism with a genome-wide range of deletion strains available and this is attributed to the feasibility of genetic manipulation of the yeast genome (Nislow & Giaever, 2007).

1.3.2 Ability to elucidate bioactivity on non-essential and essential genes

The development of the yeast deletion strain library allowed for precise genetic studies of molecular mechanisms of compounds (Winzeler et al., 1999). The use of deletion strain library for profiling a compound’s mechanism of action has been demonstrated by identifying mutant strains which exhibit hypersensitivity, thus creating a chemical genetic profile for the bioactive compounds (Giaever et al., 1999; Glaever et al., 2002; Glaever et al., 2004; Parsons et al., 2004). Chemical genetic profiling adapts the principle of synthetic lethality. Synthetic lethality is a phenomenon in which two single null mutations produce viable organisms when it occurs separately but produce inviable organisms when both mutations occur together (Figure 1A) (Parsons et al., 2004; Hartman et al., 2001). It is found that the majority of the non-essential genes have synthetically
lethal interaction with another one or two genes and with the most with 26 genes (Hartman et al., 2001). This would mean that these genes, which are coined “non-essential” genes have other redundant genes that carry out the same process but via distinct and compensatory pathways. Synthetic Genetic Array (SGA) analysis creates synthetic lethal screens by mating MATα haploid yeast query mutants with the MATa haploid yeast deletion library which identifies the molecular function of the deleted genes and thus mapping the genetic interaction network (Tong et al., 2001). This allows identification of the functions of the non-essential genes.

In order to characterise the essential genes, which are genes that cause inviability upon deletion, a library called the decreased abundance by mRNA perturbation (DAmP) library was constructed (Schuldiner et al., 2005). This library of mutant essential genes is the alternative to using inducible gene inactivation via conditional protein disruption, transcriptional shut-off, or a heterozygous diploid mutant library that essentially reduces the gene dosage to 50% (Giaever et al., 1999). On the other hand, the DAmP library was constructed by inserting an antibiotic resistance cassette into 3’ untranslated region of an essential gene, thus disrupting the mRNA transcription process and leading to lower amount of mRNA production while ensuring these yeast strains remain viable (Breslow et al., 2008). The advantage of the DAmP library over the other methods of characterising essential genes is that the essential gene disruption does not cause severe steady-state growth defects making analysis difficult.
1.3.3 Feasibility of yeast to elucidate biological activity on protein expression and localisation

Another significant advantage of yeast as compared to other model organisms is the availability of the green fluorescent-tagged protein (GFP) library. This library was generated by insertion of GFP sequence to the 3’ end of the desired open reading frame (ORF), creating a fusion protein with green fluorescence (Huh et al., 2003). This enabled observation of localisation of the proteins and quantification of the amount of fluorescence (protein expression). These measurements of localization and quantification correlated with the amount of protein measured using flow cytometry (Newman et al., 2006) and confocal microscopy (Carter et al., 2008).

1.4 Chemical Genetics to elucidate bee products mode of action in yeast

Chemical genetics is the most common method used to elucidate bioactive compounds’ mechanism of action. The core principle of chemical genetics is that a compound acts upon the model organism to mimics a mutation (Parsons, et al., 2004). Employing the same principle of synthetic lethality to characterise a gene function, the compound can act as a secondary mutation to the existing deletion or suppressed strains. Thus, the strains sensitive to the compound treatment suggest the particular biological processes affected by the compound (Figure 1.1b, Parsons et al., 2004). Combination of ~4800 non-essential deletion mutants strains (Parsons et al., 2004) and 837 DAmP (Schuldiner et al., 2005) strains libraries provides extensive coverage of the yeast
genome of 6200 genes hence allowing thorough characterisation of a compound’s mode of action. Adding compound screening against yeast GFP library gives further idea of whether the impact of compound is affecting the expression of such proteins or hindering the activity of the affected proteins.

**Figure 1.1. Chemical genetic can reproduce a synthetic lethal interactions.** (A) A synthetic lethal interaction where deletion of two genes separately results in viable individuals whereas the combination of both genes being deleted results in inviable individual. (B) Chemical genetic interactions where certain particular gene deletion that is viable becomes inviable when treated with a bioactive compound at sub-lethal concentration which would not cause inviability to the wildtype.
The chemical-genetic profiling is not restricted to screening one pure compound at a time but can accommodate a mixture of compounds for screening simultaneously. This is attractive when studying the nutritional effect of diet to the cell’s physiology. The rationale for using the mixture is that the bee products has been used in its raw form. These raw forms, similar to any other raw natural products, consist of different bioactives and proteins which may work synergistically to give its desired effect. Our aim is to employ chemical genetic screens of the discussed extracts against the yeast haploid deletion strain library to assess the genetic target of these extracts thus, evaluating the claims of the use of these extracts and identify their other potential effects.
2.0 Methods and Materials

2.1 Yeast strains

*S. cerevisiae* strains used in this thesis are as follows:

<table>
<thead>
<tr>
<th>Strain</th>
<th>Genotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>BY4741</td>
<td>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0</td>
</tr>
<tr>
<td>Δxxx</td>
<td>MATa xxxΔ::kanR; his3Δ1 leu2Δ0 met15Δ0 ura3Δ0</td>
</tr>
<tr>
<td>XXX-GFP</td>
<td>MATa XXX-GFP::natR leu2Δ0 ura3Δ0 met15Δ0</td>
</tr>
<tr>
<td>xxx-DAmP</td>
<td>MATa xxx-DAmP::kanR; his3Δ1 leu2Δ0 met15Δ0 ura3Δ0</td>
</tr>
</tbody>
</table>

Our yeast homozygous deletion library and DAmP library were purchased from OpenBiosystems. Other than BY4741, other strains are representative of respective yeast libraries.

2.2 Growth media and components

*S. cerevisiae* strains were all cultured in one of the following growth media either in agar or in broth form. Appropriate antibiotics were also supplemented to the media; final concentration of 200 µg/ml geneticin (G418) for yeast deletion and DAmP library collection, 100 µg/ml ClonNAT (Werner bioAgents) and 20 µg/ml Hygromycin (Werner bioAgents) for yeast GFP collection.
**Yeast peptone dextrose (YPD) agar:** 1% (w/v) yeast extract (Becton, Dickinson and Company), 2% (w/v) bacto-peptone (Becton, Dickinson and Company), 0.12% (w/v) adenine (Sigma-Aldrich), 2% (w/v) glucose (Sigma-Aldrich) and 2% (w/v) g agar (Invitrogen). YPD broth was prepared without agar addition.

**HEPES–buffered synthetic complete (SC+HEPES) agar:** 0.17% (w/v) yeast nitrogen base without amino acids or ammonium sulphate (Becton, Dickinson and Company), 0.1% (w/v) monosodium glutamate (Sigma-Aldrich), 0.2% (w/v) amino acid mixture to suit (Sigma-Aldrich), 20mM HEPES (Fisher Bioreagents), 2% (w/v) agar (Becton, Dickinson and Company) and 2% (w/v) glucose (Sigma-Aldrich). SC broth was prepared without agar addition.

**Synthetic dropout (SD) agar:** As with SC minus the addition of appropriate amino acid. SD broth was prepared without agar addition.

**Amino acids mixture for SC media:** 3g adenine, 2 g uracil, 2g inositol, 0.2 g para-aminobenzoic acid, 2 g alanine, 2g asparagine, 2 g aspartic acid, 2 g cysteine, 2 g glutamic acid, 2 g glutamine, 2 g glycine, 2 g histidine, 2 g isoleucine, 10 g leucine, 2 g lysine, 2 g methionine, 2 g phenylalanine, 2 g proline, 2 g serine, 2 g threonine, 2 g tryptophan, 2 g tyrosine and 2 g valine.

SD amino acid mixture prepared in this thesis is a mixture of amino acids (Invitrogen) above minus 2 g histidine (SD-His). 2 g of this mixture is added in preparation of 1L broth or agar media.
2.3 Preparation of bee products

2.3.1 Preparation of propolis extract

Propolis was obtained from GoHealthy in the form of gelatin capsules containing a viscous liquid. Propolis (10 g) was dissolved in 30ml water and incubated overnight at 30°C in a shaking incubator. Propolis was then centrifuged at 16,000 g for 20 minutes and filtered through 0.22nm pore size filter. The filtrate was labelled “crude propolis” and the residue was resuspended in 30ml methanol and incubated overnight at 30°C in shaking incubator. The methanolic propolis was centrifuged at 16,000 g for 20 minutes and filtered through 0.22nm pore size filter. The filtrate was collected and the methanol was evaporated from the methanolic extract of propolis using Labconco Centrivap - 50 cold trap machine. The methanolic extract residue was resuspended in 100% DMSO. The treatment condition of crude and methanolic extracts of propolis was completed as the percentage of volume of propolis in total volume of media (% v/v).

2.3.2 Preparation of bee pollen extract

Bee pollen was purchased from GoHealthy in the form of small granules within gelatin capsules. Pollen (1g) was dissolved in 40ml 100% DMSO and incubated overnight at 30°C in a shaking incubator. The extract was then centrifuged at 16,000 g for 20 minutes and filtered through 0.22nm pore size filter. The filtrate was labelled “crude pollen” and the pellet was resuspended in
30ml methanol and incubated overnight at 30°C in a shaking incubator. The methanolic pollen was centrifuged at 16,000 g for 20 minutes and filtered through 0.22nm pore size filter. We collected the filtrate and evaporated off the methanol from the methanolic extract of pollen using cold trap machine. The methanolic extract residue was resuspended in 100% DMSO. The treatment condition of the crude and methanolic extracts of bee pollen was completed as the percentage of volume of bee pollen in total volume of media (% v/v).

2.3.3 Preparation of bee venom

Bee venom was obtained from HoneyLab Ltd. Bee venom (0.1438g) was dissolved in 12 ml of water, vortexed at 1000 rpm for 5 minutes, and filtered through 0.22 nm syringe filter. The filtrate was collected and stored at -20°C. The treatment condition of bee venom was completed as the volume of bee venom stock (µl) in 1ml of media (µl/ml).

2.4 Dose response studies

2.4.1 Propolis and bee pollen broth dose response.

We prepared a fresh streak of BY4741 yeast strain from our frozen stock from the -80°C freezer and incubate them overnight. We inoculated a fresh streak of BY4741 yeast strain in 2ml SC broth and incubated the broth at 30°C overnight. We measured the absorbance of the overnight yeast culture and made a yeast stock at an OD$_{600}$ of 0.1 for inoculation.
We prepared a 96-well microtiter plate with each well containing 194µl of either media containing propolis or bee pollen at a range of concentrations. Each concentration was prepared in triplicate. We inoculated 6 µl of yeast on each well but some wells that will be used as blanks. We incubated the plate at 30°C and measured the absorbance at OD_{600} of the wells of the plate at 16 and 24 hours. The absorbance of each well was averaged across the corresponding triplicate and was normalised by subtracting the averaged value with the averaged value of the blanks. We analysed the absorbance by comparing the absorbance of the treated wells with the untreated control wells in the form of percentage termed “residual growth”. The residual growth was calculated as follows:

\[
\text{Residual Growth (\%)} = \frac{\text{Absorbance of averaged treated wells}}{\text{Absorbance of untreated control wells}} \times 100\%
\]

To study whether the concentrations of each bee product were simply growth inhibitory or toxic (killing the yeast), we performed another dose response using the same format as mentioned before but only at minimum inhibitory concentrations (MIC) which is the minimum concentration stop cell growth completely. After 2 hours and 6 hours of treatment with the respective bee products, we inoculated 30µl of each well on YPD agar. We incubated the agar plate at 30°C overnight and photographed the agar plate.
2.4.2 Bee venom broth dose response

Bee venom liquid dose response procedure was optimised for performing chemical genomic profiling of bee venom against both homozygous deletion library and DAmp library. With the streaked BY4741 prepared in 2.4.1, we inoculated the BY4741 strain into 5 ml of YPD broth media, incubated overnight in 30°C incubator with rotation, added 15ml of sterile water, vortexed, and aliquoted 200µl of the mixture into each well of a 96-well microtiter plate. We inoculated the yeast from the 96-well plate onto a fresh YPD agar plate and the agar plate was grown for 2 days in 30°C incubator. We then inoculated the YPD agar plate in 96 colony format into a 96-well microtiter plate containing 200µl SC+HEPES. We placed the microtiter plate in 30°C incubator for 24 hours. The following day, we prepared a new microtiter plate containing 200µl of SC+HEPES broth media with different concentrations of bee venom. We ensured each treatment condition was made in triplicate. We inoculated the yeast from the cultured 96-well microtiter plate into 96-well microtiter plate with various bee venom treatment conditions. We measured the absorbance at 590nm (OD<sub>590</sub>) using immediately after inoculation as our 0<sup>th</sup> hour. We let the yeast grow overnight inside 30°C incubator and measured absorbance at 16 and 24 hours. We normalised the OD<sub>590</sub> reading by deducting the absorbance of each well of the 16<sup>th</sup> and 24<sup>th</sup> hours’ OD<sub>590</sub> with the 0<sup>th</sup> hour OD<sub>590</sub>.
2.4.3 Propolis / bee venom / bee pollen agar dose response.

The yeast stock was prepared the same way as yeast stock from broth dose response but with two additional stocks that were one-tenth and one-hundredth of the first prepared stock. We prepared a 24-well plate with each well containing 500µl SC+HEPES agar with or without treatment of propolis, bee venom or bee pollen at specified concentrations. We inoculated 1µl of each yeast stock onto each well, incubated the plate at 30°C for 48 hours, and photographed the 24-well plate at 24 and 48 hours.

We further optimised the concentration of propolis and bee pollen for 1536 yeast colony array format by preparing different treatment conditions of bee pollen and propolis in 40ml SC+HEPES agar contained in Singer plates. We used Singer Rotor HDA to inoculate yeast from a plate from the homozygous deletion library onto each 40ml SC+HEPES agar conditions. We grew the inoculated plates in 30°C incubator and photographed each plate at 24 hours. The colony size is then measured and analysed as described in 2.5.2
2.5 Homozygous deletion library and DAmP library yeast colonies screening & image acquisition analysis

2.5.1 Homozygous deletion library and DAmP library yeast colonies screening

We prepared 40ml SC + HEPES agar media with containing 1% v/v propolis or 2% v/v bee pollen. We also prepared similar set of SC + HEPES agar media with equivalent amount of DMSO as solvent control. Each treated plates are in triplicate. We used Singer Rotor HDA to pin from our 1536 array homozygous deletion library and DAmP library onto the experimental plates. The inoculated plates are grown at 30°C and the plates were photographed after 24 hours.

2.5.2 1536-colonies array analysis

Yeast in 1536-colonies array format were used in the screening step. This array allows for four replicates of each mutant strains in each Singer plate. We used R “Gitter” software package to measure the mutant yeast colony size in 1536-array format in Singer plate (Wagih & Parts, cran-r-project.org, 2014). Gitter generate a .DAT format data accessible using Excel 2013 from our photographed yeast plates. We modified the format of the files to make log files of the containing colony sizes of all Boone library plates and their triplicates under solvent treatment and the other triplicates under extract treatment. We uploaded the log file onto Rothstein Lab’s Data Review Engine to analyse colonies and provides statistical assessment of the colony size differences under solvent treatment in
comparison to extract treatment (Dittmar et al., 2010). The Data Review Engine provides us with the growth ratio of each mutant and their corresponding p-values which we used to pick as sensitive or resistant strains. The growth ratio was measured as follows:

\[
\text{Growth ratio} = \frac{\text{Colon} \text{y size of yeast control strain}}{\text{Colon} \text{y size of yeast treated strain}}
\]

### 2.5.3 Propolis and bee pollen agar validation

The validation step is performed to verify hits that were obtained from our library screens. This step is crucial to eliminate false hits and thus ensuring the reproducibility of hits obtained. We prepared a set of SC+HEPES agar in petri dishes at concentration range of 0.03-1 % v/v. We grew deletion strains which were hits from the homozygous deletion and DAMP library screening each in 2ml SC+HEPES broth in 30°C incubator with rotation. We used a 96-well microtiter plate to prepare wells containing \(1 \times 10^6\) cells/ml and diluted down at 1:10 dilution in subsequent wells up until the sixth wells. Using multi-channel pipette, we blotted 1µl of each strain and its subsequent dilution from the microtiter plate onto the petri dishes containing propolis or bee venom at specified concentrations and petri dishes containing SC+HEPES and equivalent amount of DMSO. We incubated the petri dishes for 48 hours and photographed the yeast colonies. We chose a concentration for assessment based on the highest possible concentration that did not inhibit the growth of our BY4741 wildtype strain.
2.5.4 Bee venom broth library screening and validation

We inoculated cells from our frozen stock of homozygous deletion library and DAmP library onto YPD + Geneticin agar media. We grew the agar plates in 30°C overnight and inoculated yeast colonies from the grown agar media onto 96-well microtiter plate containing SC+HEPES 200µl media broth and incubated overnight. We inoculated yeast from the overnight broth into the prepared 96-well microtiter plates containing 200µl SC+HEPES media either with or without 0.1µl/ml bee venom. Each strain treatment was done in triplicate. We incubated the plates at 30°C and measured the absorbance at OD$_{590}$ after 16 and 24 hours post-inoculation. The absorbance reading was averaged across its replicates, and the treated and untreated strains were compared to calculate residual growth. Positive strains were identified with residual growth of less than 80% and p-value of less than 0.05. For validation studies, we grew selected strains from the screening experiment and completed the rest of the procedure identical to the library screening; the only exception was the cut-off for validated positives was residual growth of less than 70% and p-value of less than 0.05.

2.5.5 GO enrichment and analysis

GO enrichment analysis is a categorisation step of our validated positives. It annotates each positives, called GO term and divided the validated positives into groups of common GO term based on biological process, molecular function and cellular component (Ashburner et al., 2000). It assesses statistical significance of each GO term groups by comparing the positives gained in a particular Go
term from study against the total number of genes included in the study (background) that belonged to the GO term. Therefore, the more number of positives belonging to a particular GO term acquired, the more statistically enriched that GO term which are reflected upon their corresponding p-values. Such analysis tool is available on Yeastmine (Balakrishnan et al., 2012). I uploaded our positives on Yeastmine but the analysis of the homozygous deletion library and DAmP library of each bee product treatment is done separately because of different yeast backgrounds.

2. 6 Iron ion rescue

2.6.1 Iron ion rescue broth dose response

We prepared a custom agar plate by inoculating selected strains from the yeast deletion library into 96-well microtiter plate containing 200 µl SC or SC+HEPES in a format in which each strain has triplicate wells. We used Singer Rotor HDA to inoculate the yeast from the previous microtiter plate onto the YPD agar plate and grew the yeast for 24 hours at 30°C. We then used Singer Rotor HDA to inoculate the yeast from our custom agar plate into 96-well microtiter plate containing 200 µl. The inoculated 96-well plate was grown for 24 hours at 30°C. Each treatment was prepared in triplicate.

To study the effect of iron rescue under different propolis treatment concentrations, we grew select strains in a particular propolis concentration ranging from 0% (untreated) to 1% (agar screening concentration) with or
without 100 µM FeCl$_2$ supplementation. We incubated the plates for 24 hours at 30°C and measured absorbance at OD$_{590}$ using Perkin Elmer Envision Plate Reader. We normalised the absorbance reading by deducting the average absorbance reading of each triplicate wells with the average absorbance of the media without yeast triplicate of each plate and compared the normalised absorbance reading of the a strain without FeCl$_2$ supplementation to that of the same strain with 100 µM FeCl$_2$ supplementation.

To study the effect of different iron concentrations rescuing the growth of yeast under propolis treatment, we repeated the same procedure as above, but with using a fixed concentration of 0.25% propolis treatment; this was the minimal concentration of propolis to completely inhibit growth of yeast even after 48 hours and a concentration of FeCl$_2$ ranging from 0 µM to 100 µM. We also included another plate containing only SC+HEPES media as untreated control. For analysis, we measured the residual growth using the following equation:

$$\text{Residual Growth (\%)} = \frac{\text{Average strain OD reading with } 100\mu\text{M iron}}{\text{Average strain OD reading solvent control}} \times 100\%$$

We compared the residual growth of each strain and at each FeCl$_2$ concentration to that of BY4741 strains.
2.6.2 Other metal ion rescue broth dose response

We prepared 96-well microtiter containing 200µl media containing SC+HEPES media with 100µM copper chloride (CuCl₂), 100µM manganese chloride (MnCl₂), 100µM magnesium chloride (MgCl₂), or 100µM zinc chloride (ZnCl₂) and including another triplicate without metal ion supplementation. We tested the metal ion supplementation effect against propolis treatment at 0% (untreated), 0.06%, 0.25% and 1%. Each strain is tested against each 100µM metal ion supplementation and range or propolis treatment in triplicate.

2.6.3 OPERA imaging & fluorescence quantification

We replicated a GFP library copy from frozen GFP library copy from the -80°C freezer onto SC-HIS with ClonNAT and Hgh. Our GFP strains possess mCherry RFP fluorescence for nucleus identification. Overlapped GFP and RFP marker signal is indicated by yellow fluorescence signal, indicating colocalisation. The construction of the strain is described in Bircham et al. (2011). We inoculated select GFP strains chosen from propolis and bee venom validation each into 5ml tube containing 2ml SC broth and grow the strains overnight. We inoculated 10ul of each strain into a separate cuvette and measured the absorbance of each grown strain. For each strain we prepared a stock yeast which has the absorbance of OD0.1 in 1 ml 1.5 ml microcentrifuge tube. We prepared a Pelkin-Elmer 384 fluorescence plate to contain 45µl media with particular treatment conditions along with untreated media as comparison. We inoculated 15µl of each yeast stock into respective wells of the fluorescence plate. We incubated the plate for 7.5 hours for the cells to grow and reached sufficient number for
imaging and fluorescence quantification. Both GFP and RFP images were acquired using OPERA confocal microscope and GFP fluorescence quantification was performed using OPERA-bundled Acapella software, following the procedure outlined by Bircham et al. (2010) but 1000 millisecond exposure time was applied instead. The microscopic images of the GFP and RFP were overlaid.

2.7 Phosphatidylcholine (PC) quantification assay

2.7.1 Preparation of crude cell lysate

The phosphatidylcholine (PC) assay was done using the Abcam phosphatidylcholine assay kit (ab83377). We performed broth dose response as described in 2.4.3 with bee venom concentrations tested at 0.1 and 0.2 µl/ml respectively and six replicates. Following 18 hours after yeast inoculation, all six replicates of solvent control and two bee venom concentrations were pooled into 1.5ml 1.5 ml microcentrifuge tube. 10 µl of each pool was then diluted with 990 µl sterile water in cuvettes. The absorbance was measured at 660nm and the reading of each diluted pool was correlated with the cell concentration to assess the cell concentration of each pool. The cell concentration was then normalised in a way that each pool had an amount of cells equal to the pool with the least amount of cells. All normalised pools were then centrifuged at 16000g for 5 minutes. The supernatant was removed from each pool. To each pool, 100 µl of sterile glass beads along with 200 µl extraction buffer were added (0.2% v/v Triton, 1% SDS, 100mM NaCl, 10 mM Tris-Cl (pH9.0), 1 mM EDTA). Each pool was
then vortexed for 12 minutes at maximum speed. The mixture of each pool was removed and added to fresh 1.5 ml microcentrifuge tube.

2.7.2 PC assay preparation

The assay was conducted following the protocol supplied by Abcam. Briefly, a standard of 0, 2, 4, 6, 8 and 10 µl of diluted PC standard was prepared and PC assay buffer was added to bring the total volume of 50 µl in 96-well microtiter plate. PC reaction mix was prepared with PC assay buffer, PC Hydrolysis Enzyme, PC probe and PC development mix at ratio of 44:2:2:2. 50µl of each pooled sample was added to the 96-well microtiter plate in triplicate. 50µl of the PC reaction mix was added to each standard and sample well, bringing the final volume of 100 µl in each well. For the background controls, 50µl of background mix that consists of PC assay buffer, PC probe and PC development mix added at the ratio of 46:2:2 was added instead. The plate was shaken at 1000 rpm for 30 seconds, wrapped with aluminium foil and incubated at room temperature for 1 hour instead of the outlined protocol of 30 minutes. The incubated plate was then fed into Bio System Multiwell plate scanner and absorbance at 570 nm was measured for each well. The absorbance reading of each strain and treatment was normalised against their respective strain background absorbance readings. The normalised absorbance readings were then correlated with their corresponding PC concentration following the protocol supplied by Abcam. The data was then graphed and p-value was calculated for statistical significance by using Student t-test.
3.0 Results and Discussion of Propolis

3.1 Results

3.1.1 Methanolic fraction of propolis showed greater inhibition compared to crude propolis in both agar and broth media.

The methanolic extract of propolis showed greater potency than the crude water-dissolved extract in both liquid media and agar media (Figure 3.1). In crude propolis, we observed strong inhibition at 2% v/v, whereas the methanolic extract showed complete inhibition at a concentration as low as 0.25% v/v. We found similar pattern when we performed the dose response assay in agar media in which inhibition was observed in 2% crude fraction propolis but we found strong inhibition even at concentration as low as 0.5% v/v methanolic extract. Although we observed that the agar media required greater concentration of propolis to exert potency, the methanolic fraction of bee propolis was still more inhibitory compared to the crude fraction.
A.

Crude fraction propolis

![Graph showing residual growth (%) vs. concentration (% v/v) for Crude fraction propolis.

B. 

Crude fraction propolis

Methanolic fraction propolis

![Images showing different treatments of Crude and Methanolic fraction propolis.]

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Solvent control</th>
<th>SCH + 2% propolis</th>
<th>SCH + 1% propolis</th>
<th>SCH + 0.5% propolis</th>
</tr>
</thead>
</table>

Figure 3.1. (A) Residual growth of crude fraction and methanolic fraction propolis at 24th hour after inoculation. (B) BY4741 wildtype yeast colonies grown on 500µl SC+HEPES (SCH) agar media with presence of bee propolis between 0.5% - 2% v/v in $10^6$ cells on top $10^4$ cells on bottom left and $10^2$ cells on bottom right. The colony size was taken 48 hours after inoculation.

### 3.1.2 Chemical genetics screen indicates enrichment for iron ion transport

To move on to screening our homozygous deletion and DAMP libraries, we chose to proceed with using methanolic extracts of propolis because it was more potent than crude extract. To optimise the concentration for chemical genetic screening, we performed agar dose response of a plate from our deletion library collection in 1536-colonies array format. We performed the dose response assay at concentration between 0.5–2% v/v. Using ScreenMill, we picked the concentration of screening based on the median growth ratio of our $\text{his3}\Delta$ border control strains (Figure 3.2). The $\text{his3}\Delta$ strain were used to assess growth inhibition as our homozygous deletion library strains all has HIS3 gene deleted (refer section 2.1). We chose 1% v/v because the growth ratio was in the range of 1.10 to 1.20, which indicates 10-20% reduction in growth of yeast under propolis treatment, and also the fact that the growth ratio is similar to that at 1.5% and 2%. This 10-
20% growth defect leaves an 80-90% window open to detect additional growth defect due to genetic mutations in the deletion and DAmP libraries.

Figure 3.2. *his3Δ* border strains were used for selecting propolis concentration for screening. Above is the experimental plate at 1% v/v propolis treatment. The colony size was measured using Screenmill Data Review Engine (Dittmar, Reid, & Rothstein, 2010)

From the screening of propolis against yeast haploid deletion library and the DAmP library, 22 out of ~4300 deletion mutant strains exhibited a significant growth defect, i.e., mutant strains showing growth ratio of greater than 1.2 (Appendix Table B.1.1). We used SGD YeastMine web software to assess for biological process enrichment from our validated positives. From YeastMine, the top validated hits belong to response to chemical, followed by ion transport and
DNA damage response (Appendix Table A 1.1). On the other hand, 24 out of 839 strains from the DAmP library exhibited hypersensitivity against propolis treatment (Appendix Table B.1.2). We utilised YeastMine to find the most enriched biological process affected by propolis treatment. During this process, we separated hits from deletion library and DAmP library and identified that metal ion transport was the most enriched biological process, particularly iron ion transport (Appendix Table A.1.1). Other than metal ion transport, propolis also showed enrichment for response to stress and intracellular mRNA localisation. The DAmP library showed enrichment for small nucleolar RNA (snoRNA) which snoRNA is to aid specific ribosomal RNA (rRNA) modification (Dieci, Preti, & Montanini, 2009). It is interesting that the top ten most enriched processes were all consists of RRP43, SEN1, CSL4 and PRP4 (Table A.1.2).

### 3.1.3 Iron supplementation rescued growth inhibition caused by propolis.

To further investigate the target of iron metabolism, we performed a liquid dose response of propolis from 0.03% v/v to 1% v/v concentration under 100 µM FeCl₂ supplementation on our wildtype and deletion mutant strains of the genes involved in iron-ion transport (Philpott & Protechenko, 2008). We found that iron supplementation rescued the growth inhibition induced by propolis across all our deletion strains as well as the BY4741 wildtype (Figure 3.3, Table 1). The deletion strains involved in plasma membrane high-affinity iron ion transport all showed hypersensitivity toward propolis treatment at concentration as low as 0.03% v/v propolis where the complete inhibition (less than 10% residual growth) was
observed. However, \textit{aft1}Δ and \textit{aft2}Δ mutants showed hypersensitivity but not complete inhibition. Aft1p and Aft2p are both transcriptional factors that play a central role in iron ion homeostasis sharing some substrate targets (Courel, Lallet, Camadro, & Blaiseau, 2005; Yamaguchi-Iwai, Dancis, & Klausner, 1995; Blaiseau, Lesuisse, & Camadro, 2001).

Also, strains such as \textit{fet3}Δ and \textit{atx1}Δ showed greater sensitivity against propolis even with presence of 100 µM FeCl₂ compared to wildtype and other deletion strains (Figure 3.3A). The ferrireductase deletion mutants, \textit{fre1}Δ, \textit{fre2}Δ, \textit{fre3}Δ, \textit{fre6}Δ showed different response at 0.03% v/v propolis where complete inhibition was achieved in \textit{fre1}Δ, hypersensitivity was achieved in \textit{fre6}Δ and \textit{fre3}Δ, whilst \textit{fre2}Δ showed inhibition similar to BY4741 wildtype. \textit{fre4}Δ and \textit{fre5}Δ mutant strains were not investigated in this study since these strains do not exist in our deletion library. The siderophore iron transport deletion mutant strains (\textit{arn1}Δ, \textit{arn2}Δ, \textit{arn3}Δ, \textit{arn4}Δ) showed hypersensitivity against propolis at 0.03% v/v with complete inhibition achieved in \textit{arn1}Δ and \textit{arn2}Δ. Interestingly, the plasma membrane low-affinity iron (II) transport deletion mutant \textit{fet4}Δ (Dix D. R., Bridgham, Broderius, Byersdorfer, & Eide, 1994) was not inhibited at 0.03% v/v propolis indicating that the low affinity iron transporter were unaffected by propolis treatment. The vacuolar iron transporters deletion mutant \textit{fet5}Δ and \textit{fth1}Δ showed hypersensitivity against 0.03% v/v propolis treatment both at ~40% residual growth but \textit{smf3}Δ showed sensitivity comparable to wildtype. The FIT proteins deletion mutants, \textit{fit1-3}Δ all showed propolis sensitivity comparable to wildtype. Taken together, these results indicate that iron content is essential in
resisting propolis-induced growth inhibition and that some but not all mechanisms of iron uptake is essential as yeast response against propolis treatment.

(A)
**Residual Growth (%)**

**Propolis concentration (% v/v)**

---

**fet3Δ**

- **Propolis Concentration (% v/v)**: 0.03, 0.125, 0.5, 1
- **Residual Growth (%)**: 80, 60, 40, 20
- **Legend**:
  - fet3Δ
  - fet3Δ + 100μM FeCl2

---

**ccc2Δ**

- **Propolis concentration (% v/v)**: 0.03, 0.125, 0.5, 1
- **Residual Growth (%)**: 100, 80, 60, 40
- **Legend**:
  - ccc2Δ
  - ccc2Δ + 100μM FeCl2
### atx1Δ

![Graph](image)

- **Propolis Concentration (% v/v)**
- **Residual Growth (%)**

![Graph](image)

### fre1Δ

![Graph](image)

- **Concentration (% v/v)**
- **Residual Growth (%)**

![Graph](image)
**fre2Δ**

Residual Growth (%) vs. Concentration (% v/v)

- fre2Δ
- fre2Δ + 100µM FeCl2

**fre3Δ**

Residual Growth (%) vs. Concentration (% v/v)

- fre3Δ
- fre3Δ + 100µM FeCl2
(c)

**aft2Δ**

- [Graph showing residual growth against concentration for aft2Δ.]

- **aft2Δ**
- **aft2Δ + 100µM FeCl2**

**aft1Δ**

- [Graph showing residual growth against concentration for aft1Δ.]

- **aft1Δ**
- **aft1Δ + 100µM FeCl2**
(D)
(E)
(F) 

**fet4Δ**

Residual Growth (%) vs. Propolis Concentration (% v/v)

- **fet4Δ**
- **fet4Δ + 100µM FeCl2**

(G) 

**fet5Δ**

Residual Growth (%) vs. Propolis Concentration (% v/v)

- **fet5Δ**
- **fet5Δ + 100µM FeCl2**
**fre6Δ**

![Graph showing residual growth vs. concentration for fre6Δ.](image)

**fth1Δ**

![Graph showing residual growth vs. concentration for fth1Δ.](image)
Figure 3.3 Residual growth of select deletion strains under propolis treatment with or without 100 uM FeCl₂ after 24 hours inoculation. (A) BY4741 wildtype (B) High affinity plasma membrane iron ion transport. (C) Regulators of iron ion transport. (D) Siderophore-bound plasma membrane iron transporters. (E) Siderophore-bound iron retention proteins (F) Low-affinity plasma membrane iron ion transport. (G) High-affinity vacuolar iron transport. (H) Low-affinity vacuolar iron ion transport. Error bars represents standard deviation of residual growth.
<table>
<thead>
<tr>
<th></th>
<th>Residual Growth (%)</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.03%</td>
<td>0.13%</td>
<td>0.50%</td>
<td>1%</td>
</tr>
<tr>
<td>BY4741</td>
<td>65.90</td>
<td>1.83</td>
<td>2.74</td>
<td>1.10</td>
</tr>
<tr>
<td>BY4741+ 100µM FeCl₂</td>
<td>100.90</td>
<td>92.52</td>
<td>77.36</td>
<td>1.31</td>
</tr>
<tr>
<td>Δ ftr1</td>
<td>0.41</td>
<td>0.96</td>
<td>3.22</td>
<td>1.88</td>
</tr>
<tr>
<td>Δ ftr1 + 100µM FeCl₂</td>
<td>97.22</td>
<td>53.81</td>
<td>54.49</td>
<td>2.94</td>
</tr>
<tr>
<td>Δ fet3</td>
<td>0.18</td>
<td>4.98</td>
<td>2.83</td>
<td>2.61</td>
</tr>
<tr>
<td>Δ fet3 + 100µM FeCl₂</td>
<td>89.53</td>
<td>53.10</td>
<td>55.40</td>
<td>3.67</td>
</tr>
<tr>
<td>Δ ccc2</td>
<td>1.51</td>
<td>1.26</td>
<td>0.63</td>
<td>1.22</td>
</tr>
<tr>
<td>Δ ccc2 + 100µM FeCl₂</td>
<td>92.06</td>
<td>75.12</td>
<td>66.06</td>
<td>8.59</td>
</tr>
<tr>
<td>Δ atx1</td>
<td>5.14</td>
<td>1.42</td>
<td>12.52</td>
<td>2.40</td>
</tr>
<tr>
<td>Δ atx1 + 100µM FeCl₂</td>
<td>70.11</td>
<td>35.40</td>
<td>19.49</td>
<td>5.56</td>
</tr>
<tr>
<td>Δ fre1</td>
<td>11.39</td>
<td>2.14</td>
<td>4.28</td>
<td>4.16</td>
</tr>
<tr>
<td>Δ fre1 + 100µM FeCl₂</td>
<td>106.00</td>
<td>83.49</td>
<td>78.10</td>
<td>1.16</td>
</tr>
<tr>
<td>Δ fre2Δ</td>
<td>89.83</td>
<td>2.77</td>
<td>2.87</td>
<td>2.63</td>
</tr>
<tr>
<td>Δfre2 + 100µM FeCl₂</td>
<td>99.18</td>
<td>95.19</td>
<td>81.52</td>
<td>21.86</td>
</tr>
<tr>
<td>Δ fre3</td>
<td>53.82</td>
<td>2.30</td>
<td>1.75</td>
<td>1.25</td>
</tr>
<tr>
<td>Δ fre3 + 100µM FeCl₂</td>
<td>101.37</td>
<td>91.14</td>
<td>77.08</td>
<td>5.53</td>
</tr>
<tr>
<td>Δ fre2</td>
<td>34.37</td>
<td>2.41</td>
<td>3.87</td>
<td>2.17</td>
</tr>
<tr>
<td>Δ fre2 + 100µM FeCl₂</td>
<td>98.28</td>
<td>95.86</td>
<td>82.81</td>
<td>9.46</td>
</tr>
<tr>
<td>Δ aft1</td>
<td>26.13</td>
<td>1.16</td>
<td>6.88</td>
<td>1.46</td>
</tr>
<tr>
<td>Δ aft1 + 100µM FeCl₂</td>
<td>91.34</td>
<td>84.26</td>
<td>86.82</td>
<td>0.54</td>
</tr>
<tr>
<td>Δ Arn1</td>
<td>3.76</td>
<td>1.81</td>
<td>2.58</td>
<td>1.67</td>
</tr>
<tr>
<td>Δ Arn1 + 100µM FeCl₂</td>
<td>101.56</td>
<td>94.72</td>
<td>84.01</td>
<td>4.43</td>
</tr>
<tr>
<td>Δ Arn2</td>
<td>1.08</td>
<td>0.84</td>
<td>0.42</td>
<td>1.79</td>
</tr>
<tr>
<td>Δ Arn2 + 100µM FeCl₂</td>
<td>95.13</td>
<td>77.45</td>
<td>88.17</td>
<td>5.52</td>
</tr>
<tr>
<td>Δ Arn3</td>
<td>32.33</td>
<td>1.58</td>
<td>3.26</td>
<td>1.63</td>
</tr>
<tr>
<td>Δ Arn3 + 100µM FeCl₂</td>
<td>99.75</td>
<td>91.58</td>
<td>84.29</td>
<td>7.63</td>
</tr>
<tr>
<td>Δ Arn4</td>
<td>29.20</td>
<td>3.79</td>
<td>1.56</td>
<td>0.80</td>
</tr>
<tr>
<td>Δ Arn4 + 100µM FeCl₂</td>
<td>101.16</td>
<td>97.43</td>
<td>79.11</td>
<td>6.29</td>
</tr>
<tr>
<td>Δ fit1Δ</td>
<td>44.04</td>
<td>1.82</td>
<td>2.71</td>
<td>1.50</td>
</tr>
<tr>
<td>Δfit1 + 100µM FeCl₂</td>
<td>96.16</td>
<td>93.14</td>
<td>83.84</td>
<td>7.30</td>
</tr>
<tr>
<td>Δ fit2</td>
<td>74.51</td>
<td>1.26</td>
<td>3.81</td>
<td>2.41</td>
</tr>
<tr>
<td>Δ fit2 + 100µM FeCl₂</td>
<td>99.95</td>
<td>95.90</td>
<td>81.64</td>
<td>18.01</td>
</tr>
<tr>
<td>Δ fit3</td>
<td>57.56</td>
<td>1.25</td>
<td>1.15</td>
<td>1.82</td>
</tr>
<tr>
<td>Δ fit3 + 100µM FeCl₂</td>
<td>98.86</td>
<td>94.58</td>
<td>73.98</td>
<td>5.67</td>
</tr>
<tr>
<td>Δ fet4</td>
<td>103.02</td>
<td>3.60</td>
<td>12.31</td>
<td>3.83</td>
</tr>
<tr>
<td>Δ fet4 + 100µM FeCl₂</td>
<td>96.86</td>
<td>94.30</td>
<td>81.32</td>
<td>33.22</td>
</tr>
<tr>
<td>Δ fet5</td>
<td>28.50</td>
<td>1.09</td>
<td>0.76</td>
<td>0.52</td>
</tr>
<tr>
<td>Δ fet5 + 100µM FeCl₂</td>
<td>98.13</td>
<td>95.43</td>
<td>73.28</td>
<td>7.02</td>
</tr>
<tr>
<td>Δ fre6</td>
<td>18.99</td>
<td>1.51</td>
<td>2.19</td>
<td>1.90</td>
</tr>
<tr>
<td>Δfre6 + 100µM FeCl₂</td>
<td>102.33</td>
<td>99.58</td>
<td>88.39</td>
<td>14.04</td>
</tr>
<tr>
<td>Δ fth1</td>
<td>36.23</td>
<td>1.83</td>
<td>0.77</td>
<td>0.72</td>
</tr>
<tr>
<td>Δ fth1 + 100µM FeCl₂</td>
<td>98.96</td>
<td>94.86</td>
<td>80.81</td>
<td>3.76</td>
</tr>
<tr>
<td>Δ smf3</td>
<td>56.18</td>
<td>3.14</td>
<td>4.52</td>
<td>2.57</td>
</tr>
<tr>
<td>Δ smf3 + 100µM FeCl₂</td>
<td>97.31</td>
<td>95.17</td>
<td>85.77</td>
<td>8.61</td>
</tr>
</tbody>
</table>
Table 1. Tabulated residual growth of select deletion strains with or without 100 uM FeCl₂ after 24 hours inoculation.

3.1.4 Other metal ions supplementation indicates different growth rescue patterns

It is noteworthy that the high-affinity iron transporter also utilises copper ions to carry out the iron uptake (Askwith & Kaplan, 1998). Thus, it might be possible that copper ions supplementation also rescues propolis-induced growth defects similar to ion. We were also curious as to whether other metal ions would have any effect as well. The reason being propolis is rich in flavonoids and flavonoids were demonstrated to have metal ion chelation activity (Kandaswami & E. Middleton, 1997). To test this, we conducted a growth assay on BY4741, Δfre1, Δatx1, Δftr1, Δfet3, Δccc2, Δaft1, Δarn1, Δarn2, Δarn3 and Δarn4 mutant strains with 0.03% v/v methanolic fraction propolis and 100µM of CuCl₂, MnCl₂, MgCl₂, CaCl₂, or ZnCl₂ (Figure 3.4). The BY4741 wildtype indicated that iron restored growth, whereas zinc was significantly lower compared to that of no metal ion supplementation media. Zinc ion supplementation media did not show a significant difference compared to no metal ion supplementation media for fet3Δ, but we observed complete inhibition by propolis under zinc ion supplementation media.

The other metal ions showed no significant differences compared to no metal ion media in terms of residual growth in BY4741 wildtype. However, the high-affinity iron ion transport strains exhibited less than 10% residual growth under no metal ion supplementation media with the exception of Δaft1. Also, these high-
affinity iron ion transport strains showed specific growth rescue patterns on each metal ions supplementation. Δ*aft1* exhibited some growth rescue effect under propolis treatment in media containing zinc, magnesium and manganese ions. Δ*fet3* showed significant growth rescue effect for all metal ion supplementations except for zinc ion. Δ*atx1* exhibited growth rescue with only copper and iron ion supplementation. Δ*ccc2* also showed similar growth rescue with copper ion supplementation but it is also observed that there is a slight but significant growth rescue with magnesium ion supplementation as well. Δ*fre1* showed significant growth rescue effect with all but calcium ion and zinc ion supplementation. Δ*atx1*, Δ*ccc2*, and Δ*fre1* shared a similar noteworthy pattern in which copper ion supplementation rescued growth inhibition better than iron ion supplementation. In contrast, some other strains such as Δ*fet3* and Δ*ftr1* had MgCl₂ supplementation rescue growth better than CuCl₂ although the rescue is less than FeCl₂ supplementation. No metal ions were found to rescue Δ*arn1* and Δ*arn2* inhibition by propolis except for iron. Overall, all strains shared similar pattern to that of BY4741 wildtype in which FeCl₂ supplementation restored the growth phenotype while ZnCl₂ exacerbated the growth inhibition.
(A)

BY4741

Residual Growth (%)

0 20 40 60 80 100 120

No Metal  Calcium  Copper  Iron  Magnesium  Manganese  Zinc

af1Δ

Residual Growth (%)

0 20 40 60 80 100 120

No Metal  Calcium  Copper  Iron  Magnesium  Manganese  Zinc
**fet3Δ**

Residual Growth (%)

- No Metal
- Calcium
- Copper
- Iron (***
- Magnesium
- Manganase
- Zinc

---

**atx1Δ**

Residual Growth (%)

- No Metal
- Calcium
- Copper
- Iron (**
- Magnesium
- Manganase
- Zinc
Figure 3.4 Residual growth of BY4741 wildtype, under 0.03% v/v methanolic fraction propolis and various metal ion supplementation (Student’s t-test *$P < 0.05$; **$P < 0.01$; ***$P < 0.001$). Metal ions are supplemented as follows: calcium (100 µM CaCl$_2$), copper (100 µM CuCl$_2$), iron (100 µM FeCl$_2$), magnesium (100 µM MgCl$_2$), manganese (100 µM MnCl$_2$), zinc (100 µM ZnCl$_2$). Error bars represent standard deviation of averaged residual growth.
3.1.5 GFP Intensity and localisation analysis indicates upregulation of high-affinity iron ion transporters’ GFP fluorescence

Given my observation that iron supplementation rescued propolis-induced inhibition whereas zinc supplementation exacerbated the condition, I would like to know how propolis with or without iron or zinc could affect the expression and localisation of high-affinity and low-affinity iron transport proteins. To investigate this question, we evaluated GFP localization and intensity in the following strains under propolis treatment with iron or zinc supplementation: Fet3p-GFP, Aft1p-GFP, Atx1p-GFP, Ccc2p-GFP and Ftr1p-GFP which are the high affinity iron ion transport proteins; Arn1p-GFP, Arn2p-GFP, and Arn3p-GFP which are the siderophore-bound iron ion transport proteins; Fet4p-GFP which is the low-affinity plasma membrane iron ion transport; Fet5p-GFP, Fth1p-GFP and Fre6p-GFP which are the high affinity vacuolar iron transport; and Smf3p-GFP which is involved in vacuolar low-affinity iron ion transport. Plasma membrane ferrireductases Fre1-3p-GFP, plasma membrane siderophore transporter Arn4p-GFP and iron capturing complex Fit1-3p-GFP were not included in this study because these strains were not included in our yeast GFP library.

Using Acapella software, I found that GFP strains of high-affinity plasma membrane and vacuolar iron transporters exhibited significant differences compared to its solvent control with exception of Aft1p-GFP. These strains showed an increase in GFP fluorescence intensity upon propolis treatment and propolis treatment with zinc supplementation although the propolis and propolis with zinc supplementation had comparable levels of intensity indicating
upregulation of these proteins (Figure 3.5). In these strains, iron supplementation in propolis-treated media showed GFP intensity comparable to the solvent control.

(A)
Atx1p-GFP

GFP Intensity

- Solvent control
- Propolis
- Propolis + iron
- Propolis + zinc
- Iron
- Zinc

Solvent control
Propolis
Propolis + iron
Propolis + zinc
Control + iron
Control + zinc
Solvent control
Propolis
Propolis + iron
Propolis + zinc
Control + iron
Control + zinc

Ccc2p-GFP

GFP Intensity
20 40 60 80 100 120 140 160 180
Solvent control  Propolis  Propolis + iron  Propolis + zinc  Iron  Zinc

*  **
Solvent control

Propolis

Propolis + iron

Propolis + zinc

Iron

Zinc

Fet3p-GFP

GFP Intensity

0

200

400

600

800

1000

1200

1400

1600

1800

2000
**Ftr1p-GFP**

![Graph showing GFP intensity](image)

- **Solvent control**
- **Propolis**
- **Propolis + iron**
- **Propolis + zinc**
- **Iron**
- **Zinc**

![Images of cell cultures](image)

- **Solvent control**
- **Propolis**
- **Propolis + iron**
- **Propolis + zinc**
- **Control + iron**
- **Control + zinc**
(c) Arn1p-GFP

![Graph showing Arn1p-GFP intensity with different treatments.](image)

- Solvent control
- Propolis
- Propolis + iron
- Propolis + zinc
- Iron
- Zinc

![Images of GFP intensity with different treatments.](image)
Arn2p-GFP

GFP Intensity

Solvent control  Propolis  Propolis + iron  Propolis + zinc  Iron  Zinc

Solvent control  Propolis  Propolis + iron  Propolis + zinc  Control + iron  Control + zinc
Solvent control  
Propolis  
Propolis + iron  
Propolis + zinc  
Iron  
Zinc

Arn3p-GFP

GFP Intensity

Solvent control  
Propolis  
Propolis + iron

Propolis + zinc  
Control + iron  
Control + zinc
(D) 

**Fet4p-GFP**

![Graph showing GFP intensity for different treatments: Solvent control, Propolis, Propolis + iron, Propolis + zinc, Control + iron, Control + zinc.]

![Images of cells under fluorescent microscopy: Solvent control, Propolis, Propolis + iron, Propolis + zinc, Control + iron, Control + zinc.]

- **Solvent control**
- **Propolis**
- **Propolis + iron**
- **Propolis + zinc**
- **Control + iron**
- **Control + zinc**
(E)

**Fet5p-GFP**

<table>
<thead>
<tr>
<th>Condition</th>
<th>GFP Intensity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solvent control</td>
<td>10 ± 2</td>
</tr>
<tr>
<td>Propolis</td>
<td>300 ± 5</td>
</tr>
<tr>
<td>Propolis + iron</td>
<td>280 ± 4</td>
</tr>
<tr>
<td>Propolis + zinc</td>
<td>300 ± 5</td>
</tr>
<tr>
<td>Control + iron</td>
<td>15 ± 2</td>
</tr>
<tr>
<td>Control + zinc</td>
<td>15 ± 2</td>
</tr>
</tbody>
</table>

Images:
- Solvent control
- Propolis
- Propolis + iron
- Propolis + zinc
- Control + iron
- Control + zinc
Solvent control  
Propolis  
Propolis + iron  
Propolis + zinc  
Control + iron  
Control + zinc
**Figure 3.5** GFP intensity values of yeast-GFP strains (Student’s t-test \(*P < 0.05; **P < 0.01; ***P < 0.001\)).  
(A) Regulator of iron ion transport  
(B) High affinity extracellular iron ion transport.  
(C) Siderophore-bound iron ion transporters.  
(D) Low affinity extracellular iron ion transport.  
(E) Vacuolar iron ion transport.  

The high-affinity plasma membrane iron transporter GFP strains, Fet3p-GFP, Atx1p-GFP and Ccc2p-GFP showed higher intensity upon propolis treatment and propolis treatment with zinc supplementation compared to without propolis treatment (Figure 3.5A). Also, iron supplementation was found to reduce the level of GFP intensity back to untreated levels. In contrast, zinc supplementation to the media along with propolis treatment showed GFP intensity similar to the propolis only treatment for Fet3p-GFP, Atx1p-GFP and Ccc2p-GFP. Interestingly, Fet3p-GFP showed significant increase in GFP intensity under media with 100 µM ZnCl₂. This was not observed in other high-affinity iron transport GFP strains. Atx1p-GFP showed a change in localisation where the fluorescence was lost from the vacuole in the propolis-treated media and propolis-treated media with zinc supplementation compared to cytoplasmic localization in control media (Figure 3.5A). Moreover, we found some localisation of Atx1p in nucleus as well under propolis, propolis with iron supplementation and propolis with zinc supplementation treatment as observed by yellow fluorescence indicating RFP and GFP marker signal overlap. Ccc2p-GFP showed the same punctate fluorescence across all treatment conditions with greater GFP fluorescence in propolis-treated and propolis with zinc supplementation media (Figure 3.5A). On the other hand, Aft1p-GFP and Ftr1p-GFP showed no significant GFP-intensity
changes nor localization changes across all treatment conditions compared to their respective solvent control (Figure 3.5A). We observed abnormalities of Ftr1p-GFP fluorescence but we have confirmed that the Ftr1p-GFP of our collection exhibited such behaviour after repeated tests.

For the siderophore iron transporters, Arn1p-GFP, Arn2p-GFP and Arn3p-GFP did not show any significant difference in GFP-intensity or localization across all treatment conditions (Figure 3.5B). These results indicate that the propolis treatment did not affect the expression or activity of the Arn proteins. Similarly for the low-affinity iron transporter Fet4p-GFP strain, we did not observe any change in GFP intensity or localisation of GFP fluorescence across all treatment conditions (Figure 3.5C).

The vacuolar high-affinity iron transporters GFP strains Fet5p-GFP and Fth1p-GFP showed a significant increase in GFP fluorescence in propolis-treated and propolis with zinc supplementation media (Figure 3.5D). However, we did not observe localisation changes across all treated media for Fet5p-GFP and Fth1p-GFP. The vacuolar ferrireductase Fre6p-GFP and low-affinity vacuolar iron transporter did not exhibit any change in GFP intensity or localisation across all treatments (Figure 3.5E).

Based on the results from the yeast-GFP intensity and localisation analysis, propolis caused an increase in extracellular and vacuolar high-affinity iron transport GFP intensity, indicating an increase in these proteins’ expression levels under propolis treatment. In contrast, none of the low-affinity iron transport proteins showed any changes in GFP expression. Moreover, certain transporter
GFP strains also showed changes in localisation though not all high-affinity iron transport strains share that characteristic. Though we saw a significant increase in GFP intensity in Fet3p-GFP strain under the media with zinc supplementation but without propolis treatment, this pattern was not observed in all other strains. Moreover, for strains that showed significant increase of its GFP intensity under propolis treatment or propolis treatment with zinc supplementation, the intensity levels were not significantly different. Thus, the effect of zinc in respect to exacerbating the propolis-induced growth inhibition may not occur by zinc ions augmenting the bioactivity of propolis.

3.2 Discussion

We have performed liquid dose response and agar dose response in the water soluble fraction and methanolic fraction of propolis and found that the methanolic fraction is more potent in inhibiting yeast growth. We performed screening of propolis against our deletion library collection and DAmP library collection at 1% v/v and validated the results by performing dilution assay in agar media. Our validated positives showed enrichment for iron ion transport. To further investigate which iron ion transport is being affected by propolis treatment and determine whether the amount of iron in media could affect the propolis biological activity, we challenged deletion strains involved in iron ion transport with 0.06% v/v propolis with or without presence of high level of iron 100µM. We found that hypersensitivity is observed within the high-affinity iron ion transport with the exception of Δaft1 that showed strong inhibition at
0.03% v/v propolis. Also, it was observed that iron supplementation rescued growth inhibition by propolis even beyond the MIC. We also determined if other metals could provide similar phenotypic rescue. This is to confirm whether the propolis activity reduce free iron ion levels specifically or it reduces all metal ions availability as well. Each deletion strain showed specific phenotypic rescue patterns in which some strains had particular metal ions that rescued growth inhibition at varying degrees. Intriguingly, zinc ions were found to increase the inhibition by propolis.

Next, we investigated whether propolis might affect the expression and localisation of the iron transport proteins. We found a significant increase in GFP intensity for Fet3p-GFP, Atx1p-GFP and Ccc2p-GFP under propolis treatment and the iron supplementation brings the GFP intensity back to the solvent control’s level. Furthermore, propolis-treated with zinc supplementation condition also displayed higher GFP intensity at similar level to propolis-treated condition. There was also a change in localisation observed in Atx1p-GFP where the strains under propolis-treated and propolis-treated with zinc conditions showed no GFP fluorescence in vacuole. We speculated that Atx1p are released from vacuole to accommodate iron transport efficiency in response to propolis treatment. Taken together, these results suggest that propolis selectively stimulates the high-affinity iron transport proteins. Alternatively, propolis may remove iron from yeast cells and upregulate the high-affinity iron transporter proteins in response of iron deprivation inside yeast. No upregulation of Arn1p and Arn2p expression (Figure 3.5B) suggests that the siderophore iron transporters were not vital in low iron deprivation
response and that the high-affinity iron transporter being the primary means of iron uptake in yeast.

In yeast, there are three mechanisms for the uptake and vacuolar transport of iron (Figure 3.6). The first is the high affinity iron transport that is primarily
Figure 3.6 Propolis chelates iron and induces iron deprivation. (A) Iron transport process under normal iron conditions. (B) Upregulation of both extracellular and vacuolar high-affinity iron transporters following propolis treatment carried out by Ftr1p through the activity of Fet3p, Atx1p and Ccc2p. This iron uptake process begins with the activity of ferrireductase Fre1p that reduces siderophore-bound iron and also cupric copper. The activity of Fre1-3p removes siderophore, releasing free ferrous ions (Figure 3.6A). The Fet3p-Ftr1p complex oxidises the low-affinity ferrous ions to high-affinity ferric ions that are then transported into the cells via the Ftr1p subunit (Askwith & Kaplan, 1998; Stearman et al., 1996; Yun et al., 2001). The second pathway is involved in low-
affinity ferrous iron uptake which is mediated by Fet4p and SMF family proteins and their expression was found to be inversely related with high-affinity iron transport (Dix D. et al., 1997; Hassett et al., 2000). The third pathway of iron uptake is via Arn1-4p siderophore transporters in which these transporters specifically recognise siderophore for uptake into cells (Heymann et al., 2000; Yun et al., 2001).

Our results suggest that propolis acts as a metal ion chelator, particularly iron, and it removes iron ion availability from yeast (Figure 3.6B). Hypersensitivity of high-affinity iron ion transport deletion strains against propolis treatment indicates that these proteins are essential in providing response against iron deficient conditions. This is further evident from the fluorescence analysis of our GFP-tagged high-affinity iron ion transport proteins in which all transport proteins were increased in abundance upon propolis treatment. Therefore, under propolis treatment, I propose that propolis quenches the iron available from the yeast environment and in response there is an increase in high-affinity iron ion transport to maximise the uptake of iron. This model is further supported by my observation that a high iron environment is created when iron is added to growth media. The iron sequestration ability of propolis present within the media could not completely remove iron from the yeast media. This is further supported with the liquid dose response of yeast against propolis treatment under optimal iron supplementation when the propolis concentration is increased up until to 1% v/v (agar screening
concentration) causing complete inhibition of growth. In this case, 1% v/v propolis was sufficient to completely remove 100µM iron ions from the media, creating iron-deficient environment. It is noteworthy however, that Aft1p, which plays a role in positive regulation of iron ion transport, did not show any significant change in expression.

However, as observed in our metal ion rescue experiment, certain deletion strains as well as wildtype exhibit partial growth rescue phenotype under supplementation of ions other than iron or copper (Figure 3.4). A possible reason for this could be attributed to two factors; the non-high affinity iron ion transporter are non-specific in its metal ion transport capabilities (Li & Kaplan, 1998) and also that natural products such as flavonoids express metal ion chelating activities specific to each metal ion (Mladenka et al., 2011; Flora & Pachauri, 2010). In both vacuolar and extracellular environment, the non-iron metal ion supplementation outcompetes iron from being chelated by flavonoids, minimising the iron deprivation effect that potentially causes growth inhibition in yeast. Moreover, in the vacuolar environment, the high-affinity iron transporters are upregulated in response to propolis treatment, which maximises iron uptake as well as the uptake of other metal ions. This increase of non-iron ions would competitively minimise iron chelation. In contrast, for the non-high affinity iron ion transporters deletion mutants (Figure 3.4), only iron successfully rescued growth which suggests that the high-affinity iron transporters are highly specific in its activities. The high-affinity iron ion transport mutants thus result in a failure of circumventing iron deprivation by propolis. It is plausible that the variable growth rescue effects in these
mutants possibly correlates with the efficiency of that particular metal ion as electron donor to take over iron function upon propolis treatment.

Based on SGD (http://yeastgenome.org), I found only Aft1 belong under GO term for positive regulation iron ion transport. This suggests that there are other regulators of iron ion transport, such as Aft2 that might be involved in upregulating the transporter proteins that belong to another GO term, cellular iron ion homeostasis. However, the role of proteins within the context of cellular iron ion homeostasis was not explored in this study.

Metal ion chelating activity is a common factor for flavonoids although flavonoids display different degrees of effectiveness (Mladenka, et al., 2011; Kandaswami & E. Middleton, 1997). Heavy metal ions are able to prolong the production of reactive oxygen species and free radicals (Prousek, 2007), thus it is plausible that the chelating activity of flavonoids within propolis protects cells from mitochondrial damage. In the case of propolis, focusing only on iron, the propolis chelates iron, reducing the iron availability inside or outside yeast, creating a low iron condition. Yeast in turn, upregulates both extracellular and vacuolar high-affinity iron transport specifically to maximise iron content within yeast. As we did not observe any change of expression of ARN1-3p siderophore transporter and Fet4p low-affinity iron transporter, I predict that both low affinity iron transporters and siderophore iron transporters are not involved in yeast response to iron deprivation by propolis.

Different studies were carried out in analysing biological components of propolis isolated from different geographic locations. It was found that propolis
of different countries has different flavonoid compositions even within the geographical region of a country (Santos et al., 2002; Shiva et al., 2007; Uzel et al., 2005; Ahn et al., 2004). One study explored the activity of Brazilian propolis by employing a similar genome-wide screening approach similar to that used here in my thesis (Castro et al., 2011). This group demonstrated that propolis induced yeast apoptosis via the release of cytochrome c into cytoplasm and also has demonstrated an increase in reactive oxygen species (ROS). This group finding would seem to be in conflict with our findings in regard to propolis because our findings would imply propolis would cause reduction of ROS due to its iron chelation which in turn would reduce ROS production. However, another group had demonstrated that under iron deprivation, apoptosis was induced by the release of cytochrome c in cytoplasm and also increased ROS levels (Koc et al., 2005). Therefore, we propose that the iron chelating activity of propolis could potentially protect yeast cells from damage by inducing apoptosis. Our findings added a new but congruent explanation on how the biological process of yeast cells were affected by propolis. However, we did not explore the correlation between propolis with ROS levels and also markers for apoptosis in this study to confirm whether there was apoptosis in our propolis studies as previously described by (Castro et al., 2011).
4.0 Results and discussion of bee venom

4.1 Results

4.1.1 Bee venom did not show bioactivity in agar media.

We performed liquid dose response of BY4741 in SC+HEPES broth and agar dose response in SC+HEPES agar. We determined the ideal inhibition for our library screening at concentration of 0.2 µl/ml (Figure 4.1A), where the residual growth was between 80%-90% (=10-20% growth inhibition) in broth. On the other hand, we found that bee venom did not exhibit bioactivity in agar (Figure 4.1B). However, when we scaled the experiment against our deletion library, we found that our bee venom concentration was too strong during our first screening against the first 304 deletion strains in which we obtained more than 50% hits with significant growth defects. Therefore, we performed a liquid dose response of bee venom against our first 76 deletion strains (equivalent to 1 96-well plate excluding our his3∆ border strains) and picked the best concentration that resulted in approximately 10 hits. From the study, we selected 0.1 µl/ml bee venom that resulted in 10 hypersensitive strains per 96-well plate, an amount feasible for our genome-wide analysis (figure 4.1).
Figure 4.1(A). Residual growth response of BY4741 against bee venom treatment under broth SCH media at mid-log (16th hour). (B) Bee venom dose response under agar SCH media.

4.1.2 Bee venom screen indicates sensitivity in PC metabolism process

From our primary screen of ~4300 gene deletion strains and 837 DAMP strains, we found 108 gene deletion strains and 47 Damp strains that had statistically significant growth defects based on a Student’s t-test (P < 0.05) and residual growth < 70%. Of these, the growth defect was reproduced in 54 deletion
strains (Table B.2.1) and 8 DAmP strains (Table B.2.2) in an independent analysis. To acquire information of the possible biological process enrichment, I submitted these 54 genes to YeastMine and identified that histone H3-K79 methylation, global genome nucleotide-excision repair and nucleotide-excision repair were the top three most enriched biological processes (Table A.2.1). Due to the time constraints of this thesis, I chose to explore the biological process belonging to the most sensitive gene deletion mutant, which is Δsrf1 (Table B.2.1). Δsrf1, Δpsd2, Δpct1, Δept1, Δopi3, Δcki1, Δcpt1, Δpsd1, Δspo14, Δisc1 and Δlro1 which involves either in PC anabolism or catabolism (Ejsing et al., 2009). Δcds1, Δcho1 and Δect1 were also involved in PC biosynthesis but they were not included because they were absent from our deletion library collection. We performed a broth growth assay of these mutant strains with 0.1 µl/ml and 0.2 µl/ml bee venom. The 0.1 µl/ml was performed as it has the same concentration as performed during screening as explained in 4.1.1 whereas 0.2 µl/ml was the ideal concentration which we observed ~85% residual growth (i.e. ~15% growth inhibition) in the broth dose response studies (Figure 4.1A). As explained in 3.1, 0.2 µl/ml bee venom gives the ideal concentration for screening but we had too many hits at that particular concentration that we reduce the screening concentration to 0.1 µl/ml. Thus, by increasing the bee venom concentration to 0.2 µl/ml, we could discover more mutant strains that hypersensitive to bee venom treatment that would not be discovered when the dosage of bee venom was 0.1 µl/ml. We indeed found fewer hits on 0.1µl/ml where only Δpct1 and Δsrf1 was hypersensitive at BY4741 wildtype mid-log phase (16th hour) and only Δcpt1 was hypersensitive at BY4741 wildtype stationary phase (24th hour) (Figure 4.2). On the other hand, we
found Δpct1 Δcki1, and Δcpt1 to be hypersensitive at mid-log phase and Δeki1, Δpct1, Δept1, Δcki1, and Δcpt1 were hypersensitive at stationary phase. BY4741 was found to show significant difference of 87% residual growth (13% growth inhibition) at mid-log phase which is coherent with our previous broth dose response assay (Figure 4.1A). Δpsd1 appeared to be growth stimulating under bee venom treatment but the difference was not statistically significant. We had to omit Δopi3, Δisc1, and Δlro1 because they exhibit slow growth that infeasible for broth dose response experiment. The incongruent hypersensitive hits at BY4741 wildtype mid-log phase and BY4741 wildtype stationary phase is likely due to difference of growth rate across all mutant strains that either their mid-log phase comes later than the BY4741 wildtype that their hypersensitivity is observed at 24th hour but not at 16th hour or that their mid-log phase comes earlier than BY4741 wildtype that their hypersensitivity is observed at 16th hour but not at 24th hour. All these mutant strains hits could be categorised in three particular pathways relating to PC metabolism. One group consists of Eki1 and Ept1 which utilises ethanolamine to make PE, another group consists of Cki1, Pct1, Cpt1 and Ept1 that utilises choline to make PE and the final group consists of Spo14 and Srf1 that breaks down PC to PA and choline (Birner et al., 2001; Ejsing et al., 2009; Kennedy et al., 2011). These results suggests that the bee venom may inhibit specific proteins within the PC metabolic processes (Figure 4.5).
A. Figure 4.2.(A) Residual growth of deletion strains involved in phosphatidylycholine metabolism under 0.1 µl/ml bee venom treatment at BY4741 wildtype mid-log phase (16th hour) and stationary phase (24th hour).  

B. Residual growth 0.2µl/ml

---

**Figure 4.2.(A)** Residual growth of deletion strains involved in phosphatidylycholine metabolism under 0.1 µl/ml bee venom treatment at BY4741 wildtype mid-log phase (16th hour) and stationary phase (24th hour).  **(B)** Residual growth under 0.2 µl/ml bee venom treatment at
BY4741 wildtype mid-log phase (16\textsuperscript{th} hour) and stationary phase (24\textsuperscript{th} hour). (Student’s t-test \*\(P < 0.05\); **\(P < 0.01\); ***\(P < 0.001\))

4.1.3 GFP intensity and localisation studies showed suppression of Opi3p-GFP fluorescence

To study the effect of bee venom on the proteins in PC metabolism, I measured the expression levels of proteins involved in glycerol biosynthesis metabolism and PC metabolism as from Ejsing et al. (2009), in response to 0.1 \(\mu l/ml\) or 0.2 \(\mu l/ml\) bee venom. Specifically I examined Spo14p-GFP, Cki1p-GFP, Eki1p-GFP, PCt1p-GFP, Cho2p-GFP, Psd1p-GFP, Cpt1p-GFP, Ept1p-GFP and Opi3p GFP, strains similar to 4.1.2. Srf1p-GFP, Isc1p-GFP, Psd2p-GFP and lro1p-GFP were not included in this study for these strains were not available in the yeast GFP library.

We did not observe any significant changes in GFP intensity or localisation of Cho2p-GFP, Psd1p-GFP, Spo14p-GFP, Cki1p-GFP, Eki1p-GFP, PCt1p-GFP, Cpt1p-GFP, or Ept1p-GFP. Only Opi3p-GFP showed a significant decrease in GFP intensity under bee venom treatment and this was not associated with a change in localisation (Figure 4.3).
**Opi3p-GFP**

![GFP Intensity Graph]

- **Solvent control**
- **0.1 µl/ml bee venom**
- **0.2 µl/ml bee venom**
Eki1p-GFP

GFP Intensity

Solvent control 0.1 µl/ml 0.2 µl/ml

Solvent control

0.1 µl/ml bee venom

0.2 µl/ml bee venom
Solvent control

0.1 µl/ml bee venom

0.2 µl/ml bee venom
Solvent control

0.1 µl/ml bee venom

0.2 µl/ml bee venom
Solvent control

0.1 µl/ml bee venom

0.2 µl/ml bee venom
Solvent control

0.1 µl/ml bee venom

0.2 µl/ml bee venom
Solvent control

0.1 µl/ml bee venom

0.2 µl/ml bee venom

Psd1p-GFP

GFP Intensity

Solvent control  0.1 µl/ml  0.2 µl/ml
Solvent control

0.1 µl/ml bee venom

0.2 µl/ml bee venom
Solvent control

Solvent control

0.1 µl/ml bee venom

0.2 µl/ml bee venom
**Figure 4.3** GFP intensity measurement of GFP-tagged proteins involved and their respective fluorescence localisation (Student’s t-test *P < 0.05). Red fluorescence indicates nucleus location.

It is noteworthy that at 0.2 µl/ml bee venom treatment, the cells appear to be smaller and for the non-nuclear localised yeast GFP strains, the RFP fluorescence overlaps with the GFP fluorescence which the RFP signal is found in cytoplasm (e.g. Opi3p-GFP in Figure 4.3). This suggests that nucleolar proteins are now found outside nucleus implicating that the membrane integrity of yeast is compromised. These results suggest that bee venom may affect yeast’s physiology by selectively inhibiting Opi3p expression and this Opi3p downregulation effect might explain the leak of RFP signal observed at 0.2 µl/ml.

**4.1.4 PC quantification assay indicates PC decline with bee venom treatment**

To directly measure the effect of bee venom on PC metabolism, I quantified PC in BY4741 wildtype, Δsrf1 and Δspo14 with two concentrations of bee venom, 0.1 µl/ml and 0.2 µl/ml. Δspo14 was also included for we would like to observe the effect bee venom on PC metabolism under absence of PC breakdown mechanism. BY4741 and Δsrf1 showed a significant decrease of PC under 0.1 µl/ml and 0.2 µl/ml bee venom treatment (Figure 4.4). However, spo14Δ showed no significant difference under 0.1 µl/ml bee venom treatment but a significant decrease of PC concentration was observed under 0.2 µl/ml bee venom. Interestingly, the PC phenotype of spo14Δ in 0.2 µl/ml bee venom was
not as dramatic as compared to *srf1Δ* and BY4741 wildtype. These results indicate that bee venom either suppresses PC synthesis or upregulates PC catabolism.
4.2 Discussion

As I identified that bee venom was not bioactive in agar, possibly due to heat-sensitive bioactive components of bee venom (e.g. melittin) not being stable in molten agar when the bee venom was added to agar. Genome-wide analyses of bee venom were then conducted in liquid media and we determined that 108 deletion strains were hypersensitive to bee venom and we used one of the most sensitive strains (srf1Δ) to elucidate molecular mechanisms of bee venom in regulating PC metabolism.

There are two pathways in which PA could be converted to PC. The first one being the conversion to PC via PS and PE intermediates whereas the other one involves DAG intermediate. The DAG intermediate has two primary pathways; one
that produces PC directly from DAG and the other one indirectly via PE intermediate (Ejsing et al., 2009). Eki1p and Ept1 synthesise PE via CDP-ethanolamine pathway (Birner, Burgermeister, Schneiter, & Daum, 2001; Ejsing, et al., 2009) via exogenous ethanolamine as its starting materials (Birner et al., 2001). Cki1p, Cpt1p, Pct1p and Ept1p on the other hand, manufacture PC directly from exogenous choline. Ept1p is essential for both PE and PC biosynthesis to occur (Birner et al., 2001). In contrast, mutant strains *psd1Δ* and *psd2Δ*, which synthesise PE from PS under the CDP-ethanolamine pathway, were not hypersensitive to bee venom. The Kennedy pathway for manufacturing PC via Cki1p becomes essential in the *psd1Δ psd2Δ* double mutant but not *eki1Δ*, which implies that the PE-mediated Kennedy pathway for PC synthesis is insufficient to meet the minimum PC amount required for yeast viability. Therefore, the hypersensitivity observed in *eki1Δ, pct1Δ, ept1Δ cki1Δ, , and cpt1Δ* (figure 4.2B) may be due to bee venom inhibiting proteins within the CDP-ethanolamine pathway, causing reduction of PE or PC. On the other hand, the hypersensitivity of *eki1Δ* may be due to the significant reduction of PE due to the defective machinery of PE biosynthesis from exogenous ethanolamine source coupled with inhibition of PE synthesis via CDP-ethanolamine pathway by bee venom.
Furthermore, \textit{srf1}Δ but not \textit{spo14}Δ was found to be hypersensitive against bee venom. Spo14p is phospholipase D that directly breaks down PC to PA and choline and Srf1p is regulator to Spo14p activity (Ejsing et al., 2009; Kennedy et al., 2011). This suggests that unregulated Spo14p phospholipase D activity but not its absence is required for hypersensitivity. This is coherent with my hypothesis that bee venom regulates the levels of PC in yeast via inhibition of PC biosynthesis.

Protein expression level analysis by GFP intensity indicated that only Opi3p levels were downregulated by bee venom treatment. Even the proteins that function upstream of Opi3 in CDP-ethanolamine pathway, Psd1p and Cho2p did not show downregulation of expression as observed in Opi3p. This suggests that bee venom inhibits PC anabolism by suppressing Opi3p activity that catalyses the last two steps of PC biosynthesis. These results abrogate the possibility of my earlier inference that bee venom specifically inhibits PE biosynthesis from the ethanolamine pathway and PC biosynthesis from the choline pathway. Furthermore, we did not observe any increase of Spo14p upon bee venom treatment which suggests that bee venom did not increase breakdown of PC. However, it is possible that PC is being removed by activity of Lro1p; unfortunately Lro1p expression under bee venom treatment was not assessed in our study. In summary, my GFP analyses suggest that bee venom inhibits PC biosynthesis by selectively suppressing Opi3p from synthesising PC.

The results from our PC levels assay indicate that there are significant reduction of PC amount under bee venom treatment for BY4741 wildtype, \textit{srf1}Δ and \textit{spo14}Δ. \textit{spo14}Δ showed less reduction of PC under bee venom treatment.
compared to solvent control which is consistent with the function of Spo14p, a phospholipase D that breaks down PC. However, the fact that PC reduction is still observed in spo14∆ implicates other proteins that recycle constituents of PC (e.g., Lro1p).

PC is involved in membrane signalling in which it is a precursor to various secondary messenger molecules and thus implicating the significance of PC in cells to generate PC-derived messenger that results in cell growth (Wright et al., 2004). Previous studies demonstrated that inactivation of PC increased apoptosis and the cause of apoptosis linked with accumulation of the PC precursor, CDP-choline (Cui et al., 1996; Gasull et al., 2002; Williams et al., 1998). This is in line with our observation of pct1∆ being less hypersensitive to bee venom treatment compared to cpt1∆ and ept1∆ (Figure 4.2B) as Pct1p catalyses the reaction of choline phosphate and CDP to form CDP-choline (Ejsing et al., 2009). However, we did not found downregulation of Cpt1p and Ept1p in our yeast GFP assay, suggesting that the bee venom-induced cell death (via apoptosis or necrosis) is not via CDP-accumulation.
Together, our results indicate that bee venom induces growth inhibition by suppressing PC (Figure 4.6). However, Cki1p, Pct1p, Cpt1p and Ept1p that manufacture CDP-choline and convert it to PC were found not to be suppressed by bee venom (Figure 4.3). This suggests that bee venom does not induce growth inhibition by CDP-choline accumulation. Therefore, the bee venom might simply suppressing yeast growth by means of suppressing the PC-derived secondary messenger molecules or additional pro-survival signals other implicated in cell growth. Alternatively, growth inhibition may be a consequence of deficient PC
levels affecting the integrity of the cell membrane. This chapter provides possible mechanisms to explain the previous use of bee venom as an antifungal treatment (Yu et al., 2012; Samy et al., 2006; Fennel et al., 1968).

5.0 Bee pollen results and discussion

5.1 Results

5.1.1 Methanolic fraction of bee pollen showed greater inhibition compared to crude fraction in broth and agar media

The methanolic fraction of bee pollen showed greater potency than the crude fraction in both liquid and agar media (Figure 5.1). The highest concentration of crude pollen (2% v/v) yielded 80% growth inhibition, while 0.25% v/v of the methanolic extract yielded 100% growth inhibition. In contrast, the crude extract of the bee pollen was not bioactive at any concentration in agar (Figure 5.2.). We thus determined to use 2% v/v of the methanolic extract of bee pollen, a concentration that inhibited growth in 1536-yeast array agar by 10% of \textit{his3}Δ to screen the genome-wide libraries of mutant strains in agar.
Figure 5.1.(A) Residual growth of crude and methanolic fraction of pollen under different concentrations. Residual growth was measured 16 hours after yeast inoculation. (B) Agar dose response of pollen in 500µl SCH + pollen. Image was taken 48 hours after yeast inoculation.

5.1.2 Bee pollen agar screen did not show any biological process enrichment

Of the ~4300 deletions mutant strains, only 3 deletion strains were validated as being significantly inhibited by bee pollen; bem1Δ, swi4Δ and tef4Δ (Appendix Table B.3.1). From the DAMP library of 838 knockdown mutant strains, bee pollen treatment significantly inhibited growth of 10 strains; Yrb2-DAmP, Sec11-DAmP, Prp40-DamP, Sec4-DAmP, Cdc7-DAmP, Cft1-DAmP, Vrf4-DAmP, Rpc17-DAmP, Ctf13-DAmP, Rnt1-DAmP (Appendix Table B.3.2). Based on Gene Ontology (GO) enrichment analyses of these 13 genes using YeastMine, there was not enrichment for any process or pathway of the three deletion genes; however, the top three DAMP genes were enriched for the regulation of chromatin silencing...
at telomere, regulation of chromatin silencing and regulation of gene silencing. To explore further categorisation, we utilised yeast GO-SLIM Mapper (www.yeastgenome.org) to categorise each of our positives and group them in broad categories. We found that 7 out of 13 genes were involved in unique processes, while three genes were involved in mitotic cell cycle and three additional genes were involved in mRNA processing (Figure 5.2). Similar to the case of bee venom, we decided to explore the biological process of the mutant gene that was most hypersensitive to bee pollen, VRG4-DAmP. This gene is involved in GDP-mannose transport (Dean, Zhang, & Poster, 1997) along with Gda1, Psa1 and Sec53 (Caspi, 2007).
Figure 5.2 categorisation of all positive from bee pollen screening. The network was made using Cytoscape (Cline, et al., 2007)

5.1.3 Broth dose response analysis of GDP-mannose biosynthesis and transport deletion mutant strains indicates hypersensitivity in another GDP-mannose transport gene

To investigate the activity of bee pollen on GDP-mannose transport, we evaluated the growth of mutants impaired in GDP-mannose biosynthesis ($psa1\Delta$, $gda1\Delta$ and Vrg4-DAmP). Sec53 gene was not included as it was unavailable from our homozygous deletion and DAmP library. At 0.125\% v/v of bee pollen, we found that Vrg4-DAmP and $gda1\Delta$ exhibited hypersensitivity compared to BY4741 whereas $psa1\Delta$ showed no sensitivity at all (Figure 5.3,Table 2); these results are in agreement with our identification of Vrg4-DAmP being hypersensitive in our genome-wide screen.
Figure 5.3. Broth dose response assay of GDP-Mannose transport deletion mutants. The residual growth was calculated based on absorbance (OD$_{590}$) reading at 16th hour.

<table>
<thead>
<tr>
<th>Concentration (% v/v)</th>
<th>Residual Growth (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>△gda1</td>
</tr>
<tr>
<td>0.03% Pollen</td>
<td>91.06</td>
</tr>
<tr>
<td>0.125% Pollen</td>
<td>42.55</td>
</tr>
<tr>
<td>0.5% Pollen</td>
<td>34.61</td>
</tr>
<tr>
<td>2% Pollen</td>
<td>15.81</td>
</tr>
</tbody>
</table>

Table 2. Tabulated residual growth values of select strains under bee pollen treatment bee venom after 16 hour inoculation.
5.1.4 Opera image analysis of yeast GFP for GDP-mannose biosynthesis and transport strains indicates no changes in GFP fluorescence with bee pollen treatment

To investigate the effect of pollen on the expression levels of proteins in the synthesis and transport of GDP-mannose, we treated Vrg4p-GFP, Gda1p-GFP, Sec53-GFP and Psa1p-GFP strains with two concentrations of bee pollen (0.5% v/v, 2% v/v). We increased the dosage of bee pollen from 0.125% v/v in the previous 24 hour growth analysis since the GFP assay requires a more brief incubation with the bee venom (5 hours). We observed no significant changes in GFP intensity and no observable changes in localisation in all four GFP strains (Figure 5.4). Vrg4p-GFP, Gda1p-GFP and Sec53p-GFP all showed punctate fluorescence indicative of Golgi body localisation in both solvent control and also the two different bee pollen concentrations (Figure 5.4A-C). Psa1p-GFP showed fluorescence throughout the cells in control and pollen-treated media (Figure 5.4D). These results suggest that the bioactivity of bee pollen was achieved by either targeting buffering pathways that are essential under absence of Gda1p or downregulation of Vrg4p or inhibiting activity of the Vrg4p without altering the expression level and localisation of the protein.
(A) Vrg4-GFP

GFP intensity

Concentration (% v/v)

Solvent Control  0.50%  2.00%

Solvent control  0.5% v/v  2% v/v
(B)

Gda1p-GFP

<table>
<thead>
<tr>
<th>Concentration (% v/v)</th>
<th>GFP Intensity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solvent Control</td>
<td>78</td>
</tr>
<tr>
<td>0.50%</td>
<td>78</td>
</tr>
<tr>
<td>2.00%</td>
<td>78</td>
</tr>
</tbody>
</table>

Solvent control 0.5% v/v 2% v/v
A bar chart showing the GFP intensity for Psa1p-GFP at different solvent concentrations. The chart includes solvent control, 0.50%, and 2.00% solvent concentrations. The graphs indicate that the GFP intensity increases slightly with higher solvent concentrations.
Figure 5.4 GFP intensity measurement and localisation analysis of GDP-mannose transport and biosynthesis proteins indicate that there is no changes of GFP intensity and localisation.

(A) Vrg4p-GFP (B) Gda1p-GFP (C) Psa1p-GFP (D) Sec53p-GFP
5.2 Discussion

Bee pollen showed greater bioactivity in the methanolic fraction compared to the crude fraction. Screening of bee pollen against both our deletion library collection and DAMP library collection elucidated that the bioactivity of bee pollen occurs via nine processes, most notably via GDP-mannose biosynthesis based on the Vrg4-DAMP and Gda1Δ strains being sensitive to 0.125% v/v bee pollen, a concentration that is less than the 2% v/v concentration used in the genome-wide analyses.

GDP-mannose is an essential component for cells to modify proteins and lipids through N-linked and O-linked glycosylation. Vrg4p essential in regard to GDP-mannose because Vrg4p acts as GDP-mannose transporter that brings in GDP-mannose from the site of synthesis at the cytoplasm into the Golgi lumen (Dean et al., 1997). These glycosylation steps modify proteins resulting in specificity in activity and stability in structure (Herscovic & Orlean, 1993), which are necessary to give proteins and lipids GDP-mannose is made by the precursor form α-D-mannose 6-phosphate that is then acted upon by Sec53p phosphomannomutase and Psa1p GDP-mannose pyrophosphorylase to synthesise GDP-α-D-mannose (Herscovic & Orlean, 1993). Golgi body acquire GDP-mannose through the exchange of GMP as anti-porter which the latter is made available through the activity of Gda1p GDPase that breaks down GDP into GMP in Golgi lumen (Abeijon et al., 1993; Berninsone et al., 1994). Absence of Vrg4p or GDA1p expression were both implicated in reduction in glycosylated proteins and lipids (Abeijon et al., 1993; Dean et al.1997).
Figure 5.5 Bee pollen interferes GDP-mannose transport by blocking Vrg4p or Gda1p activity (A) GDP-mannose transport under normal conditions. (B) Bee pollen inhibits GDP-
mannose transport either via blocking the Vrg4p transporter or inhibiting the Gda1p enzyme from breaking down GDP to GMP.

Our results indicate the sensitivity of the mutant strains that are necessary for GDP-mannose transport but not for biosynthesis. Since we identified that growth of Vrg4p and Gda1p mutants were sensitive to bee pollen and that this growth inhibition did not include changes in the localization or expression levels of these proteins, I propose that the bee pollen interferes with the activity of Vrg4p, possibly by preventing the binding of GDP-mannose or GMP to Vrg4p (GDP-mannose transporter) or by inhibiting the binding of GDP to Gda1p (GDPase) (Figure 5.5). In both cases, GDP-mannose cannot be delivered effectively into Golgi lumen which impairs the glycosylation process. Deficiency of glycosylation would then lead to inviability of yeast. However, the effects of bee pollen on protein and lipid glycosylation were not directly examined in this study.

6. Overall conclusions and future directions

6.1 Overall conclusions

The aim of this thesis was to elucidate the biological pathways affected by the activity of propolis, bee venom and bee pollen. This thesis utilised the deletion library of 4,100 nonessential genes, the DAmP knockdown library of 838 essential genes, and select GFP strains to identify specific genes and proteins that are targets of these bee products.
In chapter 3, propolis had shown an enrichment for iron ion transport from the initial primary screen of the deletion and DAMP libraries. From there on, we conducted follow up dose responses with various metal ion supplementation and also conducted GFP fluorescence analysis to elucidate genes and proteins that are targets of propolis in inducing iron deprivation. The iron chelating bioactivity of propolis was not previously reported.

In contrast, the results of the genome-wide analyses of bee venom bioactivity in chapter 4 did not show an enrichment for any biological process or pathway. I thus chose to further investigate the most hypersensitive strain, *srf1Δ*. I determined that bee venom selectively targets Opi3p, a protein that catalyses the final two steps of PC biosynthesis. As PC homeostasis has not been previously reported as a target of bee venom, my results demonstrate that, despite lack of GO enrichment in the genome-wide analyses, it remains feasible to discover and characterise novel biological targets of a natural compound.

Similarly, the genome-wide analysis of bee pollen did not result in enrichment for any particular biological process. We instead chose one particular process required for normal growth in bee pollen-treated cells, GDP-mannose transport, for further investigation. Since we determined that normal GDP-mannose transport was required for normal growth in bee pollen-treated cells without any changes in expression levels of GDP-mannose transport proteins, we propose that GDP-mannose transport is a buffering mechanism targeted by bee pollen.
6.2 Future directions

There are a number of possibilities from our work on propolis, bee venom and bee pollen that would be useful for further investigation. In the case of propolis, the role of zinc in causing greater hypersensitivity to deletion mutant strains has not been investigated. In the case of bee venom, it would be interesting to investigate the possible effect of bee venom on Lro1p and other lipid intermediates salvaged from PC such as DAG and PA (Ejsing, et al., 2009). In the case of bee pollen, it is critical to further investigate the possible buffering network involving GDP-mannose homeostasis. In addition, there are other biological processes and pathways that were implicated to be affected by the bee products in my genome-wide analyses. Furthermore, as explained in chapter 1, different regions have different compositions and thus may possess different biological activities. We indeed observed this when our propolis showed different biological process enrichment compared to Castro group (2011). Also, this thesis explored the bee products as a mixture instead of its respective constituents. Although this is justified as these products are consumed as raw as it is, we could gain insights on which of its components attributed to its biological activities and hence characterise them. However, given the time constraint of my thesis, I was not able to further investigate these processes.
References


Giaever, Guri; Chu, Angel M.; Ni, Li; Connelly, Carla; Riles, Linda; Veronneau, Steeve; Dow, Sally; Lucau-Danilla, Ankuta; Anderson, Keith; Andre, Bruno; Arkin, Adam P.; Astromoff, Anna; Bakkoury, Mohamed El; Bangham, Rhonda; Benito, Rociz; Johnston, M. (2002). Functional profiling Saccharomyces cerevisiae genome. Nature, 418, 387-391. doi:10.1038/nature00935


Han, Sang Mi; Lee, Kwang Gill; Yeo, Joo Hong; Kweon, Hae Yong; Woo, Soon Ok; Lee, Myeong Lyeol; Baek, Ha Ju; Kim, Sun Yeou; Park, Kwan Kyu. (2007). Effect of honey bee venom on microglial cells nitric oxide and tumor necrosis factor-a production stimulated by LPS. Journal of Ethnopharmacology, 111(1), 176-181. doi:10.1016/j.jep.2006.11.008


Kwon, Young Bae; Lee, Hye Jung; Han, Ho Jae; Mar, Woung Chon; Kang, Sung Keel; Yoon, Ok Byung; Beitz, Alvin J.; Lee, Jang Hern (2002). The water-soluble fraction of bee venom produces antiinociceptive and anti-inflammatory effects on rheumatoid arthritis in rats. Life Sciences, 72(2), 191-204. doi:10.1016/S0024-3205(02)01617-X


Li, Hongzhen; Kapur, Aneesh; Yang, Jesse X.; Stivastava, Shiv; McLeod, David G.; Paredes-Guzman, Julio F.; Daugsch, Andreas; Park, Yong K.; Rhim, Johng S.. (2007). Antiproliferation of human


Moon, Dong-Oh; Park, Sung-Yong; Heo, Moon-Soo; Kim, Ki-Cheon; Park, Cheol; Ko, Woo Shin; Choi, Yung Hyun; Kim, Gi-Young. Key regulators in bee venom-induced apoptosis are Bcl-2 and caspase-3 in human leukemic U937 cells through downregulation of ERK and Akt. *International Immunopharmacology*, 6(12), 1796-1807. doi:10.1016/j.intimp.2006.07.027


Parsons, Ainslie B; Brost, Renée L; Ding, Huiming; Li, Zhijian; Zhang, Chaoying; Sheikh, Bilal; Brown, Grant W; Kane, Patricia M; hugher, Timothy R; Boone, Charles. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. *Nature Biotechnology*, 22(1), 62-69. doi:10.1038/nbt919


Tong, Amy Hin Yang; Evangelista, Marie; Parsons, Ainslie B.; Xu, Hong; Bader, Gay D.; Page, Nicholas; Robinson, Mark; Raghbizadaeh, Sasan; Hogue, Christopher W.V.; Bussey, Howard; Brenda-Andrews; Tyers, Mike; Boone, Charles. (2001). Systemic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants. *Science, 294*(5550), 2364-2368. doi:10.1126/science.1065810


Williams, S., Anthony, M., & Brindle, K. (1998). Induction of apoptosis in two mammalian cell lines results in increased levels of fructose-1,6-bisphosphate and CDP-choline as determined by 31p MRS. Society of Magnetic Resonance in Medicine, 40(3), 411-420. doi:10.1002/mrm.1910400311

Winzeler, Elizabeth A.; Shoemaker, Daniel D.; Astromoff, Anna; Liang, Hong; Anderson, Keigh; Andrew, Bruno; Bangham, Rhonda; Benito, Rocío; Boeke, Jef D.; Bussey, Howard; Chu, Angela M.; Connelly, Caria; Davis, Karen; Dietrich, Fred; Davis, Ronald W.. (1999). Functional Characterization of the S. cerevisiae Genome by Gene Deletion and Parallel Analysis. Science, 285(5429), 901-906. doi:10.1126/science.285.5429.901


### Table A.1.1 Top ten most enriched GO term for biological processes from propolis homozygous deletion library screen

<table>
<thead>
<tr>
<th>GO Term</th>
<th>P-value</th>
<th>Gene Matches</th>
</tr>
</thead>
<tbody>
<tr>
<td>metal ion transport</td>
<td>3.06E-05</td>
<td>CCC2, FTR1, KHA1, FET3</td>
</tr>
<tr>
<td>iron assimilation</td>
<td>3.22E-05</td>
<td>FTR1, FET3</td>
</tr>
<tr>
<td>iron assimilation by reduction and transport</td>
<td>3.22E-05</td>
<td>FTR1, FET3</td>
</tr>
<tr>
<td>arsenate ion transmembrane transport</td>
<td>3.22E-05</td>
<td>FTR1, FET3</td>
</tr>
<tr>
<td>transition metal ion transport</td>
<td>4.93E-05</td>
<td>CCC2, FTR1, FRE1, FET3</td>
</tr>
<tr>
<td>iron ion transport</td>
<td>7.38E-05</td>
<td>FTR1, FRE1, FET3</td>
</tr>
<tr>
<td>iron ion homeostasis</td>
<td>7.45E-05</td>
<td>CCC2, FTR1, FRE1, FET3</td>
</tr>
<tr>
<td>high-affinity iron ion transmembrane transport</td>
<td>9.63E-05</td>
<td>FTR1, FET3</td>
</tr>
<tr>
<td>iron ion transmembrane transport</td>
<td>0.000192</td>
<td>FTR1, FET3</td>
</tr>
<tr>
<td>inorganic cation transmembrane transport</td>
<td>0.000274</td>
<td>CCC2, FTR1, KHA1, FET3</td>
</tr>
</tbody>
</table>

### Table A.1.2 Top ten most enriched GO term for biological processes of from propolis DAmP library screen

<table>
<thead>
<tr>
<th>GO Term</th>
<th>P-value</th>
<th>Gene Matches</th>
</tr>
</thead>
<tbody>
<tr>
<td>snoRNA processing</td>
<td>0.005132</td>
<td>RRP43,SEN1,CSL4,PRP4</td>
</tr>
<tr>
<td>snoRNA 3'-end processing</td>
<td>0.006176</td>
<td>RRP43,SEN1,CSL4</td>
</tr>
<tr>
<td>snoRNA metabolic process</td>
<td>0.008706</td>
<td>RRP43,SEN1,CSL4,PRP4</td>
</tr>
<tr>
<td>nuclear-transcribed mRNA catabolic process, exonucleolytic, 3'-5'</td>
<td>0.011091</td>
<td>RRP43,CSL4</td>
</tr>
<tr>
<td>exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay</td>
<td>0.011091</td>
<td>RRP43,CSL4</td>
</tr>
<tr>
<td>nuclear-transcribed mRNA catabolic process, 3'-5' exonucleolytic nonsense-mediated decay</td>
<td>0.011091</td>
<td>RRP43,CSL4</td>
</tr>
<tr>
<td>nuclear-transcribed mRNA catabolic process, non-stop decay</td>
<td>0.011091</td>
<td>RRP43,CSL4</td>
</tr>
<tr>
<td>ncRNA 3'-end processing</td>
<td>0.014956</td>
<td>RRP43,SEN1,CSL4</td>
</tr>
<tr>
<td>nuclear-transcribed mRNA catabolic process, exonucleolytic</td>
<td>0.015256</td>
<td>RRP43,CSL4</td>
</tr>
<tr>
<td>exonucleolytic trimming to generate mature 3'-end of 5.8S rRNA from tricistronic rRNA transcript</td>
<td>0.015256</td>
<td>RRP43,CSL4</td>
</tr>
</tbody>
</table>

**Table A.2.1** Top ten most enriched GO term for biological processes from bee venom yeast homozygous deletion library screen

<table>
<thead>
<tr>
<th>GO term</th>
<th>p-value</th>
<th>Gene matches</th>
</tr>
</thead>
<tbody>
<tr>
<td>histone H3-K79 methylation</td>
<td>0.001549</td>
<td>DOT1,RTF1</td>
</tr>
<tr>
<td>global genome nucleotide-excision repair</td>
<td>0.001549</td>
<td>DOT1,RTF1</td>
</tr>
<tr>
<td>nucleotide-excision repair</td>
<td>0.005069</td>
<td>DOT1,RAD23,RTF1</td>
</tr>
<tr>
<td>regulation of DNA repair</td>
<td>0.006692</td>
<td>RTF1,SRS2</td>
</tr>
<tr>
<td>methionine biosynthetic process</td>
<td>0.007406</td>
<td>MET8,UTR4,YLL058W</td>
</tr>
<tr>
<td>regulation of response to DNA damage stimulus</td>
<td>0.008113</td>
<td>RTF1,SRS2</td>
</tr>
<tr>
<td>sulfur amino acid biosynthetic process</td>
<td>0.008778</td>
<td>MET8,UTR4,YLL058W</td>
</tr>
<tr>
<td>methionine metabolic process</td>
<td>0.011099</td>
<td>MET8,UTR4,YLL058W</td>
</tr>
</tbody>
</table>
snoRNA transcription from an RNA polymerase II promoter | 0.012735 | RTF1
snoRNA transcription | 0.012735 | RTF1

Appendix B

Table B.1.1: Propolis validated hits from yeast homozygous deletion library screen

<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Growth Ratio</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>MGA2</td>
<td>2.41</td>
<td>ER membrane protein involved in regulation of OLE1 transcription; inactive ER form dimerizes and one subunit is then activated by ubiquitin/proteasome-dependent processing followed by nuclear targeting; MGA2 has a paralog, SPT23, that arose from the whole genome duplication</td>
</tr>
<tr>
<td>RVS161</td>
<td>2.24</td>
<td>Amphiphysin-like lipid raft protein; interacts with Rvs167p and regulates polarization of the actin cytoskeleton, endocytosis, cell polarity, cell fusion and viability following starvation or osmotic stress</td>
</tr>
<tr>
<td>SNF5</td>
<td>1.96</td>
<td>Subunit of the SWI/SNF chromatin remodeling complex; involved in transcriptional regulation; functions interdependently in transcriptional activation with Snf2p and Snf6p; relocates to the cytosol under hypoxic conditions</td>
</tr>
<tr>
<td>EAF1</td>
<td>1.94</td>
<td>Component of the NuA4 histone acetyltransferase complex; acts as a platform for assembly of NuA4 subunits into the native complex; required for initiation of pre-meiotic DNA replication, likely due to its requirement for expression of IME1</td>
</tr>
<tr>
<td>SSD1</td>
<td>1.89</td>
<td>Translational repressor with a role in polar growth and wall integrity; regulated by Cbk1p phosphorylation to effect bud-specific translational control and localization of specific mRNAs; interacts with TOR pathway components; contains a functional N-terminal nuclear localization sequence and nucleocytoplasmic shuttling appears to be critical to Ssd1p function</td>
</tr>
<tr>
<td>CCC2</td>
<td>1.88</td>
<td>Cu(+2)-transporting P-type ATPase; required for export of copper from the cytosol into an extracytosolic compartment; similar to human proteins involved in Menkes and Wilsons diseases; protein abundance increases in response to DNA replication stress; affects TBSV model (+)RNA virus replication by regulating copper metabolism; human homologs ATP7A and ATP7B both complement yeast null mutant</td>
</tr>
<tr>
<td>BEM1</td>
<td>1.77</td>
<td>Protein containing SH3-domains; involved in establishing cell polarity and morphogenesis; functions as a scaffold protein for complexes that include Cdc24p, Ste5p, Ste20p, and Rsr1p</td>
</tr>
<tr>
<td>Gene</td>
<td>Ratio</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>FTR1</td>
<td>1.59</td>
<td>High affinity iron permease; involved in the transport of iron across the plasma membrane; forms complex with Fet3p; expression is regulated by iron; protein abundance increases in response to DNA replication stress</td>
</tr>
<tr>
<td>YDR541C</td>
<td>1.49</td>
<td>Aldehyde reductase; substrates are both aromatic and aliphatic aldehydes; uses NADPH as cofactor</td>
</tr>
<tr>
<td>PEF1</td>
<td>1.46</td>
<td>Penta-EF-hand protein; required for polar bud growth and cell wall abscission; binds calcium and zinc with different affinity; localizes to bud site in G1, bud neck in G2; binds to Sec31p and modulates COPII coat assembly</td>
</tr>
<tr>
<td>SOD2</td>
<td>1.41</td>
<td>Mitochondrial manganese superoxide dismutase; protects cells against oxygen toxicity; phosphorylated</td>
</tr>
<tr>
<td>FET3</td>
<td>1.38</td>
<td>Ferro-O2-oxidoreductase; multicopper oxidase that oxidizes ferrous (Fe2+) to ferric iron (Fe3+) for subsequent cellular uptake by transmembrane permease Ftr1p; required for high-affinity iron uptake and involved in mediating resistance to copper ion toxicity, belongs to class of integral membrane multicopper oxidases; protein abundance increases in response to DNA replication stress</td>
</tr>
<tr>
<td>SHE4</td>
<td>1.38</td>
<td>Protein containing a UCS (UNC-45/CRO1/SHE4) domain; binds to myosin motor domains to regulate myosin function; involved in endocytosis, polarization of the actin cytoskeleton, and asymmetric mRNA localization</td>
</tr>
<tr>
<td>EOS1</td>
<td>1.37</td>
<td>Protein involved in N-glycosylation; deletion mutation confers sensitivity to oxidative stress and shows synthetic lethality with mutations in the spindle checkpoint genes BUB3 and MAD1; YNL080C is not an essential gene</td>
</tr>
<tr>
<td>MAK10</td>
<td>1.35</td>
<td>Non-catalytic subunit of N-terminal acetyltransferase of the NatC type; required for replication of dsRNA virus; expression is glucose-repressible</td>
</tr>
<tr>
<td>YEL057C</td>
<td>1.32</td>
<td>Protein of unknown function involved in telomere maintenance; target of UME6 regulation</td>
</tr>
<tr>
<td>FRE1</td>
<td>1.31</td>
<td>Ferric reductase and cupric reductase; reduces siderophore-bound iron and oxidized copper prior to uptake by transporters; expression induced by low copper and iron levels</td>
</tr>
<tr>
<td>OYE3</td>
<td>1.27</td>
<td>Conserved NADPH oxidoreductase containing flavin mononucleotide (FMN); homologous to Oye2p with different ligand binding and catalytic properties; has potential roles in oxidative stress response and programmed cell death</td>
</tr>
<tr>
<td>KHA1</td>
<td>1.25</td>
<td>Putative K+/H+ antiporter; has a probable role in intracellular cation homeostasis; localized to Golgi vesicles and detected in highly purified mitochondria in high-throughput studies</td>
</tr>
<tr>
<td>GET2</td>
<td>1.24</td>
<td>Subunit of the GET complex; involved in insertion of proteins into the ER membrane; required for the retrieval of HDEL proteins from the Golgi to the ER in an ERD2 dependent fashion and for meiotic nuclear division</td>
</tr>
<tr>
<td>GRR1</td>
<td>1.24</td>
<td>F-box protein component of an SCF ubiquitin-ligase complex; modular substrate specificity factor which associates with core SCF (Cdc53p, Skp1p and Hrt1p/Rbx1p) to form the SCF(Grr1) complex; SCF(Grr1) acts as a ubiquitin-protein ligase directing ubiquitination of substrates such as: Gic2p, Mks1p, Mth1p, Cln1p, Cln2p and Cln3p; involved in carbon catabolite repression,</td>
</tr>
</tbody>
</table>
glucose-dependent divalent cation transport, glucose transport, morphogenesis, and sulfite detoxification

RTF1 1.17 Subunit of RNAPII-associated chromatin remodeling Paf1 complex; regulates gene expression by directing cotranscriptional histone modification, influences transcription and chromatin structure through several independent functional domains; directly or indirectly regulates DNA-binding properties of Spt15p and relative activities of different TATA elements; involved in transcription elongation as demonstrated by the G-less-based run-on (GLRO) assay

Table B.1.2: Propolis validated hits from yeast DAmP library screen

<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Growth Ratio</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>YGL074C</td>
<td>2.08</td>
<td>Dubious open reading frame unlikely to encode a functional protein; overlaps 5' end of essential HSF1 gene encoding heat shock transcription factor</td>
</tr>
<tr>
<td>DBP9</td>
<td>2.03</td>
<td>DEAD-box protein required for 27S rRNA processing; exhibits DNA, RNA and DNA/RNA helicase activities; ATPase activity shows preference for DNA over RNA; DNA helicase activity abolished by mutation in RNA-binding domain</td>
</tr>
<tr>
<td>ERG13</td>
<td>2.01</td>
<td>3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase; catalyzes the formation of HMG-CoA from acetyl-CoA and acetoacetyl-CoA; involved in the second step in mevalonate biosynthesis</td>
</tr>
<tr>
<td>GLN4</td>
<td>1.64</td>
<td>Glutamine tRNA synthetase; monomeric class I tRNA synthetase that catalyzes the specific glutaminylation of tRNA(Gln); N-terminal domain proposed to be involved in enzyme-tRNA interactions</td>
</tr>
<tr>
<td>ZPR1</td>
<td>1.64</td>
<td>Essential protein with two zinc fingers; present in the nucleus of growing cells but relocates to the cytoplasm in starved cells via a process mediated by Cpr1p; binds to translation elongation factor eEF-1 (Tef1p); relative distribution to the nucleus increases upon DNA replication stress</td>
</tr>
<tr>
<td>ALG13</td>
<td>1.6</td>
<td>Catalytic component of UDP-GlcNAc transferase; required for the second step of dolichyl-linked oligosaccharide synthesis; anchored to the ER membrane via interaction with Alg14p; similar to bacterial and human glycosyltransferases; protein abundance increases in response to DNA replication stress</td>
</tr>
<tr>
<td>SEC26</td>
<td>1.56</td>
<td>Essential beta-coat protein of the COPI coater; involved in ER-to-Golgi protein trafficking and maintenance of normal ER morphology; shares 43% sequence identity with mammalian beta-coat protein (beta-COP)</td>
</tr>
<tr>
<td>PRP4</td>
<td>1.55</td>
<td>Splicing factor; component of the U4/U6-U5 snRNP complex</td>
</tr>
<tr>
<td>SEC21</td>
<td>1.51</td>
<td>Gamma subunit of coater; coater is a heptameric protein complex that together with Arf1p forms the COPI coat; involved in ER to Golgi transport of selective cargo</td>
</tr>
<tr>
<td>Gene</td>
<td>Ratio</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>RIB5</td>
<td>1.5</td>
<td>Riboflavin synthase; catalyzes the last step of the riboflavin biosynthesis pathway</td>
</tr>
<tr>
<td>STH1</td>
<td>1.5</td>
<td>ATPase component of the RSC chromatin remodeling complex; required for expression of early meiotic genes; promotes base excision repair in chromatin; essential helicase-related protein homologous to Snf2p</td>
</tr>
<tr>
<td>RRP43</td>
<td>1.47</td>
<td>Exosome non-catalytic core component; involved in 3′-5′ RNA processing and degradation in both the nucleus and the cytoplasm; has similarity to E. coli RNase PH and to human hRrp43p (OIP2, EXOSC8); protein abundance increases in response to DNA replication stress</td>
</tr>
<tr>
<td>NPA3</td>
<td>1.45</td>
<td>Member of the conserved GPN-loop GTPase family; has a role in transport of RNA polymerase II to the nucleus; exhibits GTP-dependent binding to PolII; has ATPase activity; involved in sister chromatid cohesion; phosphorylated by the Pcl1p-Pho85p kinase complex; human homolog XAB1 interacts with human RNA polymerase II; protein abundance increases in response to DNA replication stress</td>
</tr>
<tr>
<td>NPA3</td>
<td>1.45</td>
<td>Exosome non-catalytic core component; involved in 3′-5′ RNA processing and degradation in both the nucleus and the cytoplasm; has similarity to human hRrp43p (OIP2, EXOSC8); protein abundance increases in response to DNA replication stress</td>
</tr>
<tr>
<td>NPA3</td>
<td>1.45</td>
<td>Exosome non-catalytic core component; involved in 3′-5′ RNA processing and degradation in both the nucleus and the cytoplasm; has similarity to human hRrp43p (OIP2, EXOSC8); protein abundance increases in response to DNA replication stress</td>
</tr>
<tr>
<td>DOP1</td>
<td>1.43</td>
<td>Golgi-localized, leucine-zipper domain containing protein; involved in endosome to Golgi transport, organization of the ER, establishing cell polarity, and morphogenesis; detected in highly purified mitochondria in high-throughput studies</td>
</tr>
<tr>
<td>SEN1</td>
<td>1.43</td>
<td>Presumed helicase and subunit of the Nrd1 complex (Nrd1p-Nab3p-Sen1p); complex interacts with the exosome to mediate 3′ end formation of some mRNAs, snRNAs, snoRNAs, and CUTs; has a separate role in coordinating DNA replication with transcription, by associating with moving replication forks and preventing errors that occur when forks encounter transcribed regions; homolog of Senataxin, which is implicated in Ataxia-Oculomotor Apraxia 2 and a dominant form of ALS</td>
</tr>
<tr>
<td>DUT1</td>
<td>1.42</td>
<td>Deoxyuridine triphosphate diphosphatase (dUTPase); catalyzes hydrolysis of dUTP to dUMP and PPI, thereby preventing incorporation of uracil into DNA during replication; critical for the maintenance of genetic stability; also has diphosphatase activity on deoxyinosine triphosphate</td>
</tr>
<tr>
<td>SPC19</td>
<td>1.42</td>
<td>Essential subunit of the Dam1 complex (aka DASH complex); complex couples kinetochores to the force produced by MT depolymerization thereby aiding in chromosome segregation; also localized to nuclear side of spindle pole body</td>
</tr>
<tr>
<td>UBA2</td>
<td>1.41</td>
<td>Subunit of heterodimeric nuclear SUMO activating enzyme E1 with Aos1p; activates Smt3p (SUMO) before its conjugation to proteins (sumoylation), which may play a role in protein targeting; essential for viability</td>
</tr>
<tr>
<td>CSL4</td>
<td>1.4</td>
<td>Exosome non-catalytic core component; involved in 3′-5′ RNA processing and degradation in both the nucleus and the cytoplasm; predicted to contain an S1 RNA binding domain; has similarity to human hCSL4p (EXOSC1)</td>
</tr>
<tr>
<td>TAO3</td>
<td>1.4</td>
<td>Component of the RAM signaling network; is involved in regulation of Ace2p activity and cellular morphogenesis, interacts with protein kinase Cbk1p and also with Kic1p</td>
</tr>
</tbody>
</table>
| TRS31  | 1.39  | Core component of transport protein particle (TRAPP) complexes I-III; TRAPP complexes are related multimeric guanine nucleotide-exchange factor for the
<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Residual Growth (%)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRF1</td>
<td>30.3</td>
<td>Regulator of phospholipase D (Spo14p); interacts with Spo14p and regulates its catalytic activity; capable of buffering the toxicity of C16:0 platelet activating factor, a lipid that accumulates intraneuronally in Alzheimer’s patients</td>
</tr>
<tr>
<td>CYC7</td>
<td>34.9</td>
<td>Cytochrome c isoform 2, expressed under hypoxic conditions; also known as iso-2-cytochrome c; electron carrier of the mitochondrial intermembrane space that transfers electrons from ubiquinone-cytochrome c oxidoreductase to cytochrome c oxidase during cellular respiration; protein abundance increases in response to DNA replication stress; CYC7 has a paralog, CYC1, that arose from the whole genome duplication</td>
</tr>
<tr>
<td>PAU8</td>
<td>34.9</td>
<td>Protein of unknown function; member of the seripauperin multigene family encoded mainly in subtelomeric regions</td>
</tr>
<tr>
<td>MET8</td>
<td>39.2</td>
<td>Bifunctional dehydrogenase and ferrochelatase; involved in the biosynthesis of siroheme, a prosthetic group used by sulfite reductase; required for sulfate assimilation and methionine biosynthesis</td>
</tr>
<tr>
<td>MBA1</td>
<td>39.8</td>
<td>Membrane-associated mitochondrial ribosome receptor; forms a complex with Mdm38p that may facilitate recruitment of mRNA-specific translational activators to ribosomes; possible role in protein export from the matrix to inner membrane</td>
</tr>
</tbody>
</table>

Table B.2.1: Bee venom validated hits from yeast homozygous deletion library
<table>
<thead>
<tr>
<th>Gene</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>KRE1</td>
<td>41.9</td>
</tr>
<tr>
<td>YEL068C</td>
<td>42.1</td>
</tr>
<tr>
<td>EDC3</td>
<td>45.03</td>
</tr>
<tr>
<td>YGR054W</td>
<td>45.1</td>
</tr>
<tr>
<td>DOT1</td>
<td>45.2</td>
</tr>
<tr>
<td>AMS1</td>
<td>45.2</td>
</tr>
<tr>
<td>NDE2</td>
<td>46.1</td>
</tr>
<tr>
<td>YEL020C</td>
<td>46.8</td>
</tr>
<tr>
<td>YDR018C</td>
<td>46.8</td>
</tr>
<tr>
<td>ATG14</td>
<td>47</td>
</tr>
<tr>
<td>MAK10</td>
<td>47</td>
</tr>
<tr>
<td>ITR1</td>
<td>47.1</td>
</tr>
<tr>
<td>YLR012C</td>
<td>47.2</td>
</tr>
</tbody>
</table>

**KRE1**<br>Cell wall glycoprotein involved in beta-glucan assembly; serves as a K1 killer toxin membrane receptor<br>

**YEL068C**<br>Protein of unknown function; expressed at both mRNA and protein levels<br>

**EDC3**<br>Non-essential conserved protein with a role in mRNA decapping; specifically affects the function of the decapping enzyme Dcp1p; mediates decay of the RPS28B mRNA via binding to both Rps28Bp (or Rps28Ap) and the RPS28B mRNA; mediates decay of the YRA1 mRNA by a different, translation-independent mechanism; localizes to cytoplasmic mRNA processing bodies; forms cytoplasmic foci upon DNA replication stress<br>

**YGR054W**<br>Eukaryotic initiation factor (eIF) 2A; associates specifically with both 40S subunits and 80S ribosomes, and interacts genetically with both eIF5b and eIF4E; homologous to mammalian eIF2A<br>

**DOT1**<br>Nucleosomal histone H3-Lys79 methylase; methylation is required for telomeric silencing, meiotic checkpoint control, and DNA damage response<br>

**AMS1**<br>Vacuolar alpha mannosidase; involved in free oligosaccharide (FOS) degradation; delivered to the vacuole in a novel pathway separate from the secretory pathway<br>

**NDE2**<br>Mitochondrial external NADH dehydrogenase; catalyzes the oxidation of cytosolic NADH; Nde1p and Nde2p are involved in providing the cytosolic NADH to the mitochondrial respiratory chain; NDE2 has a paralog, NDE1, that arose from the whole genome duplication<br>

**YEL020C**<br>Protein of unknown function with low sequence identity to Pdc1p; mRNA identified as translated by ribosome profiling data<br>

**YDR018C**<br>Probable membrane protein with three predicted transmembrane domains; similar to C. elegans F55A11.5 and maize 1-acyl-glycerol-3-phosphate acyltransferase; YDR018C has a paralog, CST26, that arose from the whole genome duplication<br>

**ATG14**<br>Autophagy-specific subunit of phosphatidylinositol 3-kinase complex I; Atg14p targets complex I to the phagophore assembly site (PAS); required for localizing additional ATG proteins to the PAS; required for overflow degradation of misfolded proteins when ERAD is saturated; homolog of human Barkor; other members are Vps34, Vps15, and Vps30p<br>

**MAK10**<br>Non-catalytic subunit of N-terminal acetyltransferase of the NatC type; required for replication of dsRNA virus; expression is glucose-repressible<br>

**ITR1**<br>Myo-inositol transporter; member of the sugar transporter superfamily; expression is repressed by inositol and choline via Opi1p and derepressed via Ino2p and Ino4p; relative distribution to the vacuole increases upon DNA replication stress; ITR1 has a paralog, ITR2, that arose from the whole genome duplication<br>

**YLR012C**<br>Putative protein of unknown function; YLR012C is not an essential gene
<table>
<thead>
<tr>
<th>Gene</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>RTF1</td>
<td>Subunit of RNAPII-associated chromatin remodeling Paf1 complex; regulates gene expression by directing cotranscriptional histone modification, influences transcription and chromatin structure through several independent functional domains; directly or indirectly regulates DNA-binding properties of Spt15p and relative activities of different TATA elements; involved in transcription elongation as demonstrated by the G-less-based run-on (GLRO) assay</td>
</tr>
<tr>
<td>SRS2</td>
<td>DNA helicase and DNA-dependent ATPase; involved in DNA repair and checkpoint recovery, needed for proper timing of commitment to meiotic recombination and transition from Meiosis I to II; blocks trinucleotide repeat expansion; affects genome stability; disassembles Rad51p nucleoprotein filaments during meiotic recombination; functional homolog of human RTEL1</td>
</tr>
<tr>
<td>YOL114C</td>
<td>Putative protein of unknown function with similarity to human ICT1; has prokaryotic factors that may function in translation termination; YOL114C is not an essential gene</td>
</tr>
<tr>
<td>YNL319W</td>
<td>Dubious open reading frame; unlikely to encode a functional protein, based on available experimental and comparative sequence data; partially overlaps the verified gene HXT14</td>
</tr>
<tr>
<td>SNC1</td>
<td>Vesicle membrane receptor protein (v-SNARE); involved in the fusion between Golgi-derived secretory vesicles with the plasma membrane; proposed to be involved in endocytosis; member of the synaptobrevin/VAMP family of R-type v-SNARE proteins; SNC1 has a paralog, SNC2, that arose from the whole genome duplication</td>
</tr>
<tr>
<td>UTR4</td>
<td>Protein with sequence similarity to acireductone synthases; involved in methionine salvage; found in both the cytoplasm and nucleus</td>
</tr>
<tr>
<td>NGR1</td>
<td>RNA binding protein that negatively regulates growth rate; interacts with the 3' UTR of the mitochondrial porin (POR1) mRNA and enhances its degradation; overexpression impairs mitochondrial function; interacts with Dhh1p to mediate POR1 mRNA decay; expressed in stationary phase</td>
</tr>
<tr>
<td>MDS3</td>
<td>Putative component of the TOR regulatory pathway; negative regulator of early meiotic gene expression; required, with Pmd1p, for growth under alkaline conditions; has an N-terminal kelch-like domain; MDS3 has a paralog, PMD1, that arose from the whole genome duplication</td>
</tr>
<tr>
<td>AFG1</td>
<td>Protein that may act as a chaperone for cytochrome c oxidase subunits; conserved protein; may act as a chaperone in the degradation of misfolded or unassembled cytochrome c oxidase subunits; localized to matrix face of the mitochondrial inner membrane; member of the AAA family but lacks a protease domain</td>
</tr>
<tr>
<td>CAJ1</td>
<td>Nuclear type II J heat shock protein of the E. coli dnaJ family; contains a leucine zipper-like motif, binds to non-native substrates for presentation to Ssa3p, may function during protein translocation, assembly and disassembly</td>
</tr>
<tr>
<td>RAD23</td>
<td>Protein with ubiquitin-like N terminus; subunit of Nuclear Excision Repair Factor 2 (NEF2) with Rad4p that binds damaged DNA; enhances protein deglycosylation activity of Png1p; also involved, with Rad4p, in ubiquitylated protein turnover</td>
</tr>
<tr>
<td>Gene ID</td>
<td>Score</td>
</tr>
<tr>
<td>---------</td>
<td>-------</td>
</tr>
<tr>
<td>PHO8</td>
<td>53</td>
</tr>
<tr>
<td>AGP2</td>
<td>54.8</td>
</tr>
<tr>
<td>SMY2</td>
<td>55.4</td>
</tr>
<tr>
<td>MKT1</td>
<td>55.4</td>
</tr>
<tr>
<td>PRE9</td>
<td>55.8</td>
</tr>
<tr>
<td>YLL059C</td>
<td>56.3</td>
</tr>
<tr>
<td>YGL138C</td>
<td>56.4</td>
</tr>
<tr>
<td>ECL1</td>
<td>56.4</td>
</tr>
<tr>
<td>BUD9</td>
<td>57.5</td>
</tr>
<tr>
<td>VAB2</td>
<td>57.7</td>
</tr>
<tr>
<td>YGR153W</td>
<td>57.7</td>
</tr>
<tr>
<td>NPP2</td>
<td>57.8</td>
</tr>
<tr>
<td>Gene</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>genome duplication, and an npp1 npp2 double mutant exhibits reduced dityrosine fluorescence relative to the single mutants</td>
<td></td>
</tr>
<tr>
<td>GPP2</td>
<td>DL-glycerol-3-phosphate phosphatase involved in glycerol biosynthesis; also known as glycerol-1-phosphatase; induced in response to hyperosmotic or oxidative stress, and during diauxic shift; GPP2 has a paralog, GPP1, that arose from the whole genome duplication</td>
</tr>
<tr>
<td>NUT1</td>
<td>Component of the RNA polymerase II mediator complex; mediator is required for transcriptional activation and also has a role in basal transcription</td>
</tr>
<tr>
<td>RMR1</td>
<td>Protein required for meiotic recombination and gene conversion; null mutant displays reduced PIS1 expression and growth defects on non-fermentable carbon sources and minimal media; GFP-fusion protein localizes to both cytoplasm and nucleus</td>
</tr>
<tr>
<td>HAT2</td>
<td>Subunit of the Hat1p-Hat2p histone acetyltransferase complex; required for high affinity binding of the complex to free histone H4, thereby enhancing Hat1p activity; similar to human RbAp46 and 48; has a role in telomeric silencing</td>
</tr>
<tr>
<td>CAD1</td>
<td>AP-1-like basic leucine zipper (bZIP) transcriptional activator; involved in stress responses, iron metabolism, and pleiotropic drug resistance; controls a set of genes involved in stabilizing proteins; binds consensus sequence TTACTAA; CAD1 has a paralog, YAP1, that arose from the whole genome duplication</td>
</tr>
<tr>
<td>ADE16</td>
<td>Enzyme of 'de novo' purine biosynthesis; contains both 5-aminimidazole-4-carboxamide ribonucleotide transformylase and inosine monophosphate cyclohydrase activities; ADE16 has a paralog, ADE17, that arose from the whole genome duplication; ade16 ade17 mutants require adenine and histidine</td>
</tr>
<tr>
<td>GTT2</td>
<td>Glutathione S-transferase capable of homodimerization; functional overlap with Gtt2p, Grx1p, and Grx2p; protein abundance increases in response to DNA replication stress</td>
</tr>
<tr>
<td>YGL117W</td>
<td>Putative protein of unknown function</td>
</tr>
<tr>
<td>GAT3</td>
<td>Protein containing GATA family zinc finger motifs; involved in spore wall assembly; sequence similarity to GAT4, and the double mutant gat3 gat4 exhibits reduced dityrosine fluorescence relative to the single mutants</td>
</tr>
<tr>
<td>MFG1</td>
<td>Regulator of filamentous growth; interacts with FLO11 promoter and regulates FLO11 expression; binds to transcription factors Flo8p and Mss11p; green fluorescent protein (GFP)-fusion protein localizes to the nucleus; YDL233W is not an essential gene</td>
</tr>
<tr>
<td>LSB1</td>
<td>Negative regulator of actin nucleation-promoting factor activity; interacts with Las17p, a homolog of human Wiskott-Aldrich Syndrome protein (WASP), via an N-terminal SH3 domain, and along with PIN3 cooperatively inhibits the nucleation of actin filaments; overexpression blocks receptor-mediated endocytosis; protein increases in abundance and forms nuclear foci in</td>
</tr>
</tbody>
</table>
response to DNA replication stress; LSB1 has a paralog, PIN3, that arose from the whole genome duplication

<table>
<thead>
<tr>
<th>Gene</th>
<th>Residual Growth (%)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>YLL058W</td>
<td>68.3</td>
<td>Putative protein of unknown function with similarity to Str2p; Str2p is a cystathionine gamma-synthase important in sulfur metabolism; YLL058W is not an essential gene</td>
</tr>
<tr>
<td>PYC1</td>
<td>69</td>
<td>Pyruvate carboxylase isoform; cytoplasmic enzyme that converts pyruvate to oxaloacetate; differentially regulated than isoform Pyc2p; mutations in the human homolog are associated with lactic acidosis; PYC1 has a paralog, PYC2, that arose from the whole genome duplication</td>
</tr>
</tbody>
</table>

Table B.2.2: Bee venom validated hits from yeast DAMP library screen

<table>
<thead>
<tr>
<th>Gene</th>
<th>Residual Growth (%)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCL1</td>
<td>25</td>
<td>Alpha 1 subunit of the 20S proteasome; involved in the degradation of ubiquitinated substrates; 20S proteasome is the core complex of the 26S proteasome; essential for growth; detected in the mitochondria</td>
</tr>
<tr>
<td>DOP1</td>
<td>34.8</td>
<td>Golgi-localized, leucine-zipper domain containing protein; involved in endosome to Golgi transport, organization of the ER, establishing cell polarity, and morphogenesis; detected in highly purified mitochondria in high-throughput studies</td>
</tr>
<tr>
<td>UBA2</td>
<td>39</td>
<td>Subunit of heterodimeric nuclear SUMO activating enzyme E1 with Aos1p; activates Smt3p (SUMO) before its conjugation to proteins (sumoylation), which may play a role in protein targeting; essential for viability</td>
</tr>
<tr>
<td>RPN8</td>
<td>42.2</td>
<td>Essential non-ATPase regulatory subunit of the 26S proteasome; has similarity to the human p40 proteasomal subunit and to another S. cerevisiae regulatory subunit, Rpn11p</td>
</tr>
<tr>
<td>ERG26</td>
<td>52.8</td>
<td>C-3 sterol dehydrogenase; catalyzes the second of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis</td>
</tr>
<tr>
<td>NSL1</td>
<td>64</td>
<td>Essential component of the MIND kinetochore complex; joins kinetochore subunits contacting DNA to those contacting microtubules; required for accurate chromosome segregation; complex consists of Mtw1p Including Nnf1p-Nsl1p-Dsn1p (MIND)</td>
</tr>
</tbody>
</table>
Table B.3.1: Bee pollen validated hits from yeast homozygous deletion library screen

<table>
<thead>
<tr>
<th>Systematic name</th>
<th>Gene Name</th>
<th>Growth Ratio</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>YBR200W</td>
<td>BEM1</td>
<td>1.56</td>
<td>Protein containing SH3-domains; involved in establishing cell polarity and morphogenesis; functions as a scaffold protein for complexes that include Cdc24p, Ste5p, Ste20p, and Rsr1p</td>
</tr>
<tr>
<td>YKL081W</td>
<td>TEF4</td>
<td>1.27</td>
<td>Gamma subunit of translational elongation factor eEF1B; stimulates the binding of aminoacyl-tRNA (AA-tRNA) to ribosomes by releasing eEF1A (Tef1p/Tef2p) from the ribosomal complex</td>
</tr>
<tr>
<td>YER111C</td>
<td>SWI4</td>
<td>1.22</td>
<td>DNA binding component of the SBF complex (Swi4p-Swi6p); a transcriptional activator that in concert with MBF (Mbp1-Swi6p) regulates late G1-specific transcription of targets including cyclins and genes required for DNA synthesis and repair; Slt2p-independent regulator of cold growth; acetylation at two sites, K1016 and K1066, regulates interaction with Swi6p</td>
</tr>
</tbody>
</table>

Table B.3.2: Bee pollen validated hits from yeast DAmP library screen

<table>
<thead>
<tr>
<th>Systematic name</th>
<th>Gene Name</th>
<th>Growth Ratio</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>YGL225W</td>
<td>VRG4</td>
<td>1.96</td>
<td>Golgi GDP-mannose transporter; regulates Golgi function and glycosylation in Golgi; VRG4 has a paralog, HVG1, that arose from the whole genome duplication</td>
</tr>
<tr>
<td>YDR301W</td>
<td>CFT1</td>
<td>1.84</td>
<td>RNA-binding subunit of the mRNA cleavage and polyadenylation factor; involved in poly(A) site recognition and required for both pre-mRNA cleavage and polyadenylation, 51% sequence similarity with mammalian AAUAA-binding subunit of CPSF</td>
</tr>
<tr>
<td>YIL063C</td>
<td>YRB2</td>
<td>1.69</td>
<td>Protein of unknown function; involved in nuclear processes of the Ran-GTPase cycle; involved in nuclear protein export; contains Ran Binding Domain and FxFG repeats; interacts with Srm1p, GTP-Gsp1p, Rna1p and Crm1p; relocalizes to the cytosol in response to hypoxia; not essential for viability</td>
</tr>
<tr>
<td>YIR022W</td>
<td>SEC11</td>
<td>1.6</td>
<td>18kDa catalytic subunit of the Signal Peptidase Complex (SPC); the Signal Peptidase Complex cleaves the signal sequence of proteins targeted to the endoplasmic reticulum; other members are Spc1p, Spc2p, Spc3p, and Sec11p</td>
</tr>
<tr>
<td>---------</td>
<td>-------</td>
<td>-----</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>YFL005W</td>
<td>SEC4</td>
<td>1.6</td>
<td>Rab family GTPase; essential for vesicle-mediated exocytic secretion and autophagy; associates with the exocyst component Sec15p and may regulate polarized delivery of transport vesicles to the exocyst at the plasma membrane</td>
</tr>
<tr>
<td>YDL017W</td>
<td>CDC7</td>
<td>1.43</td>
<td>DDK (Dbf4-dependent kinase) catalytic subunit; required for origin firing and replication fork progression in mitotic S phase through phosphorylation of Mcm2-7p complexes and Cdc45p; kinase activity correlates with cyclidal DBF4 expression; required for pre-meiotic DNA replication, meiotic DSB formation, recruitment of the monopolin complex to kinetochores during meiosis I and as a gene-specific regulator of the meiosis-specific transcription factor Ndt80p</td>
</tr>
<tr>
<td>YKL012W</td>
<td>PRP40</td>
<td>1.35</td>
<td>U1 snRNP protein involved in splicing; interacts with the branchpoint-binding protein during the formation of the second commitment complex</td>
</tr>
<tr>
<td>YMR094W</td>
<td>CTF13</td>
<td>1.35</td>
<td>Subunit of the CBF3 complex; CBF3 binds to the CDE III element of centromeres, bending the DNA upon binding, and may be involved in sister chromatid cohesion during mitosis</td>
</tr>
<tr>
<td>YJL011C</td>
<td>RPC17</td>
<td>1.34</td>
<td>RNA polymerase III subunit C17; physically interacts with C31, C11, and TFIIIB70; may be involved in the recruitment of pol III by the preinitiation complex; protein abundance increases in response to DNA replication stress; relocalizes to the cytosol in response to hypoxia</td>
</tr>
<tr>
<td>YMR239C</td>
<td>RNT1</td>
<td>1.34</td>
<td>Nuclear dsRNA-specific ribonuclease (RNase III); involved in rDNA transcription, RNA processing and U2 snRNA 3' end formation by cleavage of a stem-loop structure at the 3' end of U2 snRNA; involved in polyadenylation-independent transcription termination; involved in the cell wall stress response, regulating the degradation of cell wall integrity and morphogenesis checkpoint genes</td>
</tr>
</tbody>
</table>